Yoon Hang 'John' Kim, MD, MPH Tree-Gas Breath Testing for SIBO About Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified integrative medicine physician with over 20 years of clinical experience. He completed his integrative medicine fellowship at the University of Arizona under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture, and integrative/holistic medicine. Through his telemedicine practice, Dr. Kim specializes in utilizing LDN or Low Dose Naltrexone for treating autoimmune conditions, chronic pain, integrative oncology, and complex conditions including fibromyalgia, chronic fatigue, MCAS, and mold toxicity. He is the author of three books and more than 20 articles, and has helped establish integrative medicine programs at institutions nationwide. Professional:   www.yoonhangkim.com  | Clinical:   www.directintegrativecare.com Three-Gas Breath Testing for SIBO I've been treating SIBO for over two decades now, and for most of that time, the standard two-gas breath test served us reasonably well. We'd measure hydrogen and methane, apply the consensus thresholds, and treat accordingly. But something always nagged at me: there were patients who had all the classic symptoms—the bloating, the unpredictable bowels, the fatigue—yet their breath tests came back essentially flat. Normal. Nothing to see here. Except there clearly was something to see. These weren't anxious patients imagining symptoms. They were suffering, and we were missing something. The addition of hydrogen sulfide measurement to breath testing has, for me, filled in that diagnostic gap. It's not revolutionary—it's more like finding the missing piece of a puzzle you've been working on for years. The Cross-Feeding Problem Here's what's actually happening in the gut that explains those 'flatline' results. When bacteria ferment carbohydrates, they produce hydrogen. That's straightforward. But hydrogen doesn't just sit there—it's currency in the microbial economy. Other organisms consume it. Methanogens like Methanobrevibacter smithii  grab hydrogen to make methane. Sulfate-reducing bacteria— Desulfovibrio  being the main culprit—use it to produce hydrogen sulfide. So if you've got a gut dominated by sulfate-reducers, they're essentially vacuuming up all the hydrogen before it can be detected in your breath. The test looks negative, but there's plenty of bacterial overgrowth happening. We just couldn't see it. Once I understood this, those frustrating false-negative cases started making sense. What the Numbers Mean The 2017 North American Consensus  gave us standardized cutoffs, which was helpful. Before that, everyone was using slightly different criteria and it made comparing results a headache. For hydrogen, we're looking for a rise of 20 ppm or more above baseline within the first 90 minutes. That timing matters—it tells us the fermentation is happening in the small intestine, not the colon. For methane, it's simpler: 10 ppm at any point suggests methanogen overgrowth. And for hydrogen sulfide, the threshold that's emerged from validation studies is 3 ppm. I should note—these are guidelines, not gospel. A patient with levels just under threshold but classic symptoms still warrants clinical attention. The numbers inform the decision; they don't make it for you. Different Gases, Different Presentations What I find clinically useful about three-gas testing is how well the gas patterns correlate with symptom clusters. It's not perfect, but it's consistent enough to guide treatment. Hydrogen-Dominant These are your classic SIBO patients—bloating that gets worse as the day goes on, diarrhea or loose stools, cramping after meals. They tend to respond well to dietary carbohydrate restriction. I usually start with a modified low-FODMAP approach rather than the strict elimination version. Pulling out onions, garlic, wheat, and the high-fructose fruits often provides meaningful relief. Most people don't need to live on rice and chicken forever. Methane-Dominant Constipation is the hallmark here. Methane actually slows gut motility—it's not just a marker of overgrowth, it's directly contributing to the problem. These patients need the dietary piece, but they also need prokinetic support. I emphasize meal spacing—four to five hours between meals—to let the migrating motor complex do its job. That 'housekeeping wave' can't run properly if you're grazing all day. Hydrogen Sulfide-Dominant This is the group we were missing with two-gas testing. The telltale sign is really foul-smelling gas—sulfurous, rotten-egg quality. They often have diarrhea, but what strikes me is how many have systemic symptoms: fatigue, brain fog, sometimes even joint pain. The dietary approach here is different—we're restricting sulfur-containing foods rather than just fermentable carbs. That means cutting back on eggs, red meat, and the cruciferous vegetables that are otherwise so healthy. It's counterintuitive for patients who've been told to eat more broccoli. Treatment Implications Knowing the gas pattern changes how I prescribe. The ACG guidelines  support rifaximin for hydrogen-dominant SIBO, and it works well for most. But methane is stubborn—those archaea are tough organisms. I usually need to combine rifaximin with either neomycin or metronidazole to make a dent. For hydrogen sulfide overgrowth, the emerging approach is rifaximin plus bismuth. The bismuth does double duty—it binds hydrogen sulfide directly and helps break up biofilms. I've been pleased with the results, though I'll admit the evidence base is still developing. Medications alone rarely provide lasting resolution. The bigger question is always: why did the overgrowth happen in the first place? Was there a motility issue? Inadequate stomach acid? Structural problem? Addressing root causes is what separates temporary improvement from durable results. The Bottom Line Three-gas testing isn't a revolution—it's a refinement. But for patients who've been told their tests are normal despite ongoing symptoms, that refinement can be the difference between continued suffering and finally getting answers. If you've had inconclusive breath testing in the past, it may be worth retesting with a platform that measures all three gases. As Dr. Weil taught me years ago: marry yourself to results, not methods. When new tools improve our diagnostic accuracy, we should use them. Three-Gas Breath Testing for SIBO At www.directinegrativecare.com Dr. Kim is dedicated to guiding you on your path to wellness through a deeply personalized and supportive approach. We focus on integrative medicine, looking beyond symptoms to uncover the root causes of chronic conditions and develop a treatment plan tailored specifically to your unique health journey. By combining compassionate care with innovative therapies, our goal is to empower you with the knowledge and tools needed to achieve lasting health. We invite you to explore our website to learn more about how our patient-centered practice can help you find balance and vitality.  Yoon Hang Kim MD Integrative & Functional Medicine Physician Virtual Practice Serving IA, IL, MO, FL, GA, and TX www.directintegrativecare.com References Pimentel, M., Saad, R. J., Long, M. D., & Rao, S. S. C. (2020). ACG clinical guideline: Small intestinal bacterial overgrowth. American Journal of Gastroenterology, 115 (2), 165–178. https://doi.org/10.14309/ajg.0000000000000501 Rezaie, A., Buresi, M., Lembo, A., Lin, H., McCallum, R., Rao, S., Schmulson, M., Valdovinos, M., Zakko, S., & Pimentel, M. (2017). Hydrogen and methane-based breath testing in gastrointestinal disorders: The North American Consensus. American Journal of Gastroenterology, 112 (5), 775–784. https://doi.org/10.1038/ajg.2017.46 Takakura, W., & Pimentel, M. (2020). Small intestinal bacterial overgrowth and irritable bowel syndrome—An update. Frontiers in Psychiatry, 11 , 664. https://doi.org/10.3389/fpsyt.2020.00664

Edited by Yoon Hang Kim MD MPH About Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified integrative medicine physician with over 20 years of clinical experience. He completed his integrative medicine fellowship at the University of Arizona under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture, and integrative/holistic medicine. Through his telemedicine practice, Dr. Kim specializes in utilizing LDN or Low Dose Naltrexone for treating autoimmune conditions, chronic pain, integrative oncology, and complex conditions including fibromyalgia, chronic fatigue, MCAS, and mold toxicity. He is the author of three books and more than 20 articles, and has helped establish integrative medicine programs at institutions nationwide. Professional:   www.yoonhangkim.com  | Clinical:   www.directintegrativecare.com LDN Alpha Lipoic Acid Integrative Medicine Cancer treatment has evolved well beyond chemotherapy and radiation. Integrative oncology—an approach that addresses both disease progression and quality of life—has become an increasingly important part of comprehensive cancer care. Among the most promising low-toxicity interventions is low-dose naltrexone (LDN). Originally developed as an opioid antagonist at higher doses, LDN shows remarkable immunomodulatory and anti-proliferative properties when given at doses between 1.5 and 4.5 milligrams. This review examines the current evidence for LDN in cancer treatment, how it works, and how it fits into broader oncology protocols. Understanding Low-Dose Naltrexone in Cancer Therapy At standard doses of 50 milligrams, naltrexone works as a continuous opioid receptor blocker—that's how it's used in addiction medicine. But something interesting happens at low doses. When we give just 3.0–4.5 mg at bedtime, LDN creates only a brief blockade of opioid receptors lasting a few hours. This temporary blockade triggers a rebound effect: the body responds by ramping up production of endogenous opioids, particularly endorphins and opioid growth factor (OGF, also known as met-enkephalin). The opioid growth factor axis is central to how LDN works. OGF interacts with its receptor (OGFr) to inhibit DNA synthesis and cell division—a mechanism especially relevant in rapidly dividing cancer cells. By enhancing this natural regulatory system, LDN may suppress tumor growth while boosting immune surveillance. This dual mechanism sets it apart from conventional cytotoxic therapies. LDN may also be one of the first glial cell modulators used for chronic pain management. I should be clear: LDN for cancer remains investigational. There are no official clinical guidelines or FDA approval for this use. That said, LDN has shown benefit in reducing symptoms in fibromyalgia, Crohn's disease, multiple sclerosis, and complex regional pain syndrome—giving us insight into its broader immunomodulatory effects. The Berkson Protocol: LDN Combined with Alpha-Lipoic Acid The most documented application of LDN in integrative oncology comes from the work of Dr. Burton M. Berkson, who developed the ALA/N protocol combining intravenous alpha-lipoic acid with oral LDN. This approach uses the complementary mechanisms of both compounds to target cancer through multiple pathways. Alpha-lipoic acid (ALA) is a naturally occurring mitochondrial cofactor with remarkable versatility. In normal cells, ALA acts as a potent antioxidant—scavenging reactive oxygen species and regenerating other antioxidants like glutathione, vitamin C, and vitamin E. But here's what makes it particularly interesting for oncology: within the tumor microenvironment, ALA exhibits pro-oxidant properties that selectively disrupt cancer cell metabolism. It can protect healthy tissues while promoting oxidative stress in malignant cells. The Berkson Protocol is most often used for solid tumors, where surgical and metabolic interventions are commonly considered together. Mechanisms of Action: How LDN and ALA Target Cancer LDN's therapeutic potential in cancer stems from several interconnected mechanisms. First, the transient opioid receptor blockade triggers upregulation of endorphins and OGF, which interact with OGFr to inhibit tumor cell proliferation. This antiproliferative effect has been demonstrated across multiple cancer cell lines, including pancreatic, hepatocellular, and renal malignancies. Second, LDN enhances immune surveillance by modulating natural killer cell activity and T-lymphocyte function. Cancer cells frequently evade immune detection; LDN may help restore the immune system's ability to recognize and eliminate malignant cells. Third, LDN reduces inflammatory cytokines—specifically TNF-alpha and IL-6—and modulates the inflammatory tumor microenvironment that often promotes cancer progression. Alpha-lipoic acid adds complementary anti-cancer mechanisms. ALA interferes with the Warburg effect—cancer cells' preferential reliance on glycolysis over oxidative phosphorylation—by promoting mitochondrial function and disrupting altered glucose metabolism. It also modulates NF-κB signaling, a key inflammatory pathway involved in cancer progression, metastasis, and treatment resistance. The combination of ALA's metabolic effects with LDN's immunomodulatory properties creates a comprehensive approach to cancer management. Clinical Evidence: Case Reports and Outcomes Let me be upfront: we don't have large randomized controlled trials for LDN in cancer. What we do have is a compelling body of case reports and small prospective series documenting remarkable outcomes, particularly in cancers with typically poor prognosis. LDN appears well-tolerated—the most common side effect is vivid dreams, seen in about 37% of patients. Pancreatic Cancer Dr. Berkson's initial publication described a patient with metastatic pancreatic adenocarcinoma—cancer that had already spread to the liver—who achieved long-term survival exceeding three years on the ALA/N protocol. The patient remained asymptomatic and professionally active. If you know anything about pancreatic cancer, you know this is extraordinary; median survival for metastatic disease typically measures in months, not years. Subsequent reports documented three additional cases: one patient survived 39 months with liver metastases, another showed no evidence of disease on PET imaging after five months, and a third patient—who had concurrent pancreatic cancer, retroperitoneal metastases, B-cell lymphoma, AND prostate adenocarcinoma—demonstrated complete radiographic resolution of detectable malignancy. Renal Cell Carcinoma, Prostate Cancer, and Other Malignancies Extended survival and disease stabilization have been reported in stage IV renal cell carcinoma and hepatocellular carcinoma, with patients experiencing rapid improvements in energy and overall well-being after starting IV ALA. One notable case involved a patient with biopsy-confirmed follicular B-cell lymphoma who achieved complete radiographic resolution of metabolically active lymph nodes within six months using LDN alone—suggesting that LDN monotherapy may offer benefit in certain hematological malignancies. A prospective case series by Schwartz and colleagues described disease stabilization across various advanced cancers, including dramatic PSA reduction in hormone-resistant prostate cancer. Toxicity was limited to transient nausea and occasional vomiting—a far cry from conventional chemotherapy's side effect profile. Protocol Specifications and Clinical Implementation The standard Berkson protocol consists of intravenous alpha-lipoic acid at 300–600 mg given two to three times weekly, combined with oral LDN at 3.0–4.5 mg at bedtime. Adjunctive components typically include oral alpha-lipoic acid (about 600 mg daily), selenium (200 mcg), and silymarin (900–1,200 mg daily) for liver protection. Some practitioners add intravenous vitamin C and hydroxycitrate. Lifestyle modifications are essential—this isn't just about taking supplements. We emphasize anti-inflammatory nutrition, stress reduction, and appropriate physical activity. The protocol's safety profile is favorable; most adverse effects are limited to mild GI symptoms and occasional skin reactions. But proper patient selection and monitoring remain critical. This should be implemented under the guidance of physicians experienced in integrative oncology. One important note: patients must inform their healthcare provider about other medications they're taking. LDN's interaction with opioid analgesics is a serious consideration—LDN is contraindicated in patients currently taking opioids, as even low doses can precipitate withdrawal. LDN Beyond Cancer: Chronic Pain and Inflammation While this article focuses on cancer, it's worth noting that LDN has shown consistent benefit for chronic pain conditions including fibromyalgia, Crohn's disease, and complex regional pain syndrome. The mechanism appears to involve modulation of microglial cells and enhancement of endogenous opioid production, reducing inflammatory responses and pain perception. In my practice, I've found LDN's exceptional safety profile makes it a valuable option for patients seeking relief from persistent pain. LDN has also been shown to reduce not only self-reported pain in Crohn's disease but also objective markers of inflammation and disease severity. The anti-inflammatory effect extends beyond the central nervous system—we see suppressed inflammatory agents in peripheral macrophages as well. Integrating LDN into Comprehensive Cancer Care LDN offers several practical advantages as an integrative oncology intervention. It's well-tolerated, inexpensive, and has minimal drug interactions (with the important exception of opioids). It can often be used alongside conventional treatments, potentially improving quality of life and supporting immune function during chemotherapy or radiation. For patients who have exhausted standard therapies or prefer low-toxicity approaches, LDN represents a reasonable option for disease stabilization and symptom management. But I want to be clear about the limitations. The evidence base consists primarily of case reports and small series—not large randomized trials. LDN remains investigational and isn't FDA-approved for cancer. And while it may stabilize disease and improve quality of life, it shouldn't replace evidence-based conventional treatments when those are appropriate. It's an adjunct, not a replacement. Conclusion: The Future of LDN in Integrative Oncology The evidence supporting LDN in cancer treatment, while still emerging, makes a compelling case for its inclusion in the integrative oncology toolkit. The ALA/LDN protocol pioneered by Dr. Berkson has documented remarkable outcomes in patients with advanced malignancies typically associated with poor prognosis. The mechanistic rationale—combining immunomodulation, antiproliferative effects, and metabolic targeting—provides a coherent scientific framework for these clinical observations. Cancer isn't a single disease—it's many different conditions, and LDN's role may vary depending on cancer type and stage. Early detection and accurate diagnosis remain critical for optimizing outcomes. But for patients seeking comprehensive, low-toxicity approaches to cancer management, LDN represents a promising option that deserves serious consideration within the context of individualized, evidence-informed care. As integrative oncology continues to evolve, LDN exemplifies the potential for repurposing established medications to address unmet needs in cancer care. The protocol's favorable safety profile, low cost, and preliminary evidence of efficacy warrant continued investigation through rigorous clinical trials. I look forward to seeing where the research takes us. LDN Alpha Lipoic Acid Integrative Medicine Disclaimer: This article is for educational purposes only and does not constitute medical advice. The ALA/LDN protocol remains investigational and should only be pursued under the guidance of qualified healthcare providers. Patients should discuss all treatment options with their oncology team. — About the Author At www.directinegrativecare.com Dr. Kim is dedicated to guiding you on your path to wellness through a deeply personalized and supportive approach. We focus on integrative medicine, looking beyond symptoms to uncover the root causes of chronic conditions and develop a treatment plan tailored specifically to your unique health journey. By combining compassionate care with innovative therapies, our goal is to empower you with the knowledge and tools needed to achieve lasting health. We invite you to explore our website to learn more about how our patient-centered practice can help you find balance and vitality.  Clinical Practice: www.directintegrativecare.com Professional: www.yoonhangkim.com References Berkson BM, Rubin DM, Berkson AJ. The long-term survival of a patient with pancreatic cancer with metastases to the liver after treatment with the intravenous alpha-lipoic acid/low-dose naltrexone protocol. Integrative Cancer Therapies. 2006;5(1):83-89. Berkson BM, Rubin DM, Berkson AJ. Reversal of signs and symptoms of a B-cell lymphoma in a patient using only low-dose naltrexone. Integrative Cancer Therapies. 2007;6(3):293-296. Berkson BM, Rubin DM, Berkson AJ. Revisiting the ALA/N (α-lipoic acid/low-dose naltrexone) protocol for people with metastatic and nonmetastatic pancreatic cancer: A report of 3 new cases. Integrative Cancer Therapies. 2009;8(4):416-422. Berkson BM, Calvo Riera F. The long-term survival of a patient with stage IV renal cell carcinoma following an integrative treatment approach including the intravenous α-lipoic acid/low-dose naltrexone protocol. Integrative Cancer Therapies. 2018;17(3):986-993. Schwartz L, Buhler L, Icard P, Lincet H, Steyaert JM. Metabolic treatment of cancer: Intermediate results of a prospective case series. Anticancer Research. 2014;34(2):973-980. Yan S, Lu J, Chen B, et al. The multifaceted role of alpha-lipoic acid in cancer prevention, occurrence, and treatment. Antioxidants. 2024;13(8):897. Superti F, Russo R. Alpha-lipoic acid: Biological mechanisms and health benefits. Antioxidants. 2024;13(10):1228.

About Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified integrative medicine physician with over 20 years of clinical experience. He completed his integrative medicine fellowship at the University of Arizona under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture, and integrative/holistic medicine. Through his telemedicine practice, Dr. Kim specializes in utilizing LDN or Low Dose Naltrexone for treating autoimmune conditions, chronic pain, integrative oncology, and complex conditions including fibromyalgia, chronic fatigue, MCAS, and mold toxicity. He is the author of three books and more than 20 articles, and has helped establish integrative medicine programs at institutions nationwide. Professional:   www.yoonhangkim.com  | Clinical:   www.directintegrativecare.com ALA and LDN for Cancer San Antonio Quincy Dr. Burton M. Berkson pioneered the use of intravenous alpha-lipoic acid (ALA) combined with oral low-dose naltrexone (LDN) as an integrative protocol for patients with advanced cancer and liver disease. His initial case reports, dating back to the early 2000s, described unexpectedly long-term survival and clinical improvement in patients with metastatic pancreatic cancer and renal cell carcinoma who had exhausted conventional therapies. [1] [2] [3]  The protocol’s safety and apparent efficacy prompted calls for further clinical investigation. Pharmacological Mechanisms    ALA is a mitochondrial cofactor with potent antioxidant and anti-inflammatory properties. It acts by scavenging reactive oxygen species, regenerating endogenous antioxidants (notably glutathione), chelating metal ions, and modulating inflammatory pathways. [4] [5] [6] [7]  In cancer, ALA exhibits unique pro-oxidative effects within the tumor microenvironment, disrupting redox balance and inhibiting cell proliferation through mechanisms such as Grb2-mediated signaling and interference with glycolytic metabolism (Warburg effect). [8] [9] [10]  LDN transiently blocks opioid receptors, upregulating endogenous opioids and the opioid growth factor axis, which can inhibit tumor growth and modulate immune responses. [1] [2] [3] Protocol Specifications    The Berkson protocol typically consists of: - Intravenous ALA:  300–600 mg, 2–3 times per week. - Oral LDN:  4.5 mg nightly. Adjuncts may include intravenous vitamin C and hydroxycitrate, alongside lifestyle modifications. [2] [11] Clinical Evidence    Case reports and small series document long-term survival and disease stabilization in patients with metastatic pancreatic cancer, renal cell carcinoma, and other chemoresistant malignancies treated with the ALA/LDN protocol. [1] [2] [3] [11]  For example, Berkson et al. reported patients with metastatic pancreatic cancer and RCC achieving multi-year survival and radiographic remission, with minimal toxicity. [1] [2] [3]  Schwartz et al. described a prospective case series in advanced cancer, noting disease stabilization and dramatic PSA reduction in hormone-resistant prostate cancer, with toxicity limited to transient nausea and vomiting. [11]  Preclinical studies and reviews support ALA’s anti-proliferative effects in cancer models and its role in metabolic and oxidative stress modulation. [4] [8] [5] [6] [9] [10] In hepatology, ALA has shown promise in metabolic dysfunction-associated steatotic liver disease (MASLD), reducing hepatic fat accumulation and oxidative damage. [12]  Its favorable safety profile and antioxidant effects make it a candidate for adjunctive therapy in liver toxicity and chronic liver disease. [4] [5] [12] Implications for Contemporary Practice    The Berkson protocol offers a low-toxicity, integrative approach for patients with advanced cancer or liver disease, especially those who have failed standard therapies.  While case reports and small series suggest benefit, robust randomized controlled trials are lacking, and the protocol remains investigational. ALA’s mechanisms—antioxidant, pro-oxidant in cancer, metabolic modulation—are well characterized, and LDN’s immunomodulatory effects are increasingly recognized. The protocol’s safety profile is favorable, with most adverse effects limited to mild gastrointestinal symptoms and skin reactions. [4] [5] [11] Conclusion    The intravenous ALA/LDN protocol represents a promising, low-toxicity adjunct in integrative oncology and hepatology. Its historical use, mechanistic rationale, and encouraging clinical reports warrant further controlled studies to define its efficacy and optimal patient selection. Until then, it should be considered experimental, with careful monitoring and informed consent. References:    - Historical case reports and protocol details: [1] [2] [3] [11] - Mechanisms and pharmacology: [4] [8] [5] [6] [7] [9] [10] - Hepatotoxicity and liver disease: [12] Meet Yoon Hang Kim MD Dr. Kim's Telemedicine Practice Dr. Kim is dedicated to guiding you on your path to wellness through a deeply personalized and supportive approach. We focus on integrative medicine, looking beyond symptoms to uncover the root causes of chronic conditions and develop a treatment plan tailored specifically to your unique health journey. By combining compassionate care with innovative therapies, our goal is to empower you with the knowledge and tools needed to achieve lasting health. We invite you to explore our website to learn more about how our patient-centered practice can help you find balance and vitality.  www.directintegrativecare.com Yoon Hang Kim MD Integrative & Functional Medicine Physician Virtual Practice Serving IA, IL, MO, FL, GA, and TX www.directintegrativecare.com References Revisiting the ALA/N (Alpha-Lipoic Acid/Low-Dose Naltrexone) Protocol for People With Metastatic and Nonmetastatic Pancreatic Cancer: A Report of 3 New Cases . Berkson BM, Rubin DM, Berkson AJ. Integrative Cancer Therapies. 2009;8(4):416-22. doi:10.1177/1534735409352082. The Long-Term Survival of a Patient With Stage IV Renal Cell Carcinoma Following an Integrative Treatment Approach Including the Intravenous Α-Lipoic Acid/Low-Dose Naltrexone Protocol . Berkson BM, Calvo Riera F. Integrative Cancer Therapies. 2018;17(3):986-993. doi:10.1177/1534735417747984. The Long-Term Survival of a Patient With Pancreatic Cancer With Metastases to the Liver After Treatment With the Intravenous Alpha-Lipoic Acid/Low-Dose Naltrexone Protocol . Berkson BM, Rubin DM, Berkson AJ. Integrative Cancer Therapies. 2006;5(1):83-9. doi:10.1177/1534735405285901. Therapeutic Applications of Alpha-Lipoic Acid: A Review of Clinical and Preclinical Evidence (1998-2024) . Carnib BL, Souza EV, Floresta LRS, et al. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 2025;191:118480. doi:10.1016/j.biopha.2025.118480. Alpha-Lipoic Acid: Biological Mechanisms and Health Benefits . Superti F, Russo R. Antioxidants (Basel, Switzerland). 2024;13(10):1228. doi:10.3390/antiox13101228. Advances in Α-Lipoic Acid for Disease Prevention: Mechanisms and Therapeutic Insights . Wang Y, Jiang S, He Y, Pang P, Shan H. Molecules (Basel, Switzerland). 2025;30(9):1972. doi:10.3390/molecules30091972. Potential for Novel Therapeutic Uses of Alpha Lipoic Acid . Fasipe B, Faria A, Laher I. Current Medicinal Chemistry. 2023;30(35):3942-3954. doi:10.2174/0929867329666221006115329. The Multifaceted Role of Alpha-Lipoic Acid in Cancer Prevention, Occurrence, and Treatment . Yan S, Lu J, Chen B, et al. Antioxidants (Basel, Switzerland). 2024;13(8):897. doi:10.3390/antiox13080897. Lipoic Acid Inhibits Cell Proliferation of Tumor Cells in Vitro and in Vivo . Feuerecker B, Pirsig S, Seidl C, et al. Cancer Biology & Therapy. 2012;13(14):1425-35. doi:10.4161/cbt.22003. Integrated Transcriptomic and Proteomic Analyses Reveal Ɑ-Lipoic Acid-Regulated Cell Proliferation via Grb2-Mediated Signalling in Hepatic Cancer Cells . Yang L, Wang X, Xu J, et al. Journal of Cellular and Molecular Medicine. 2018;22(6):2981-2992. doi:10.1111/jcmm.13447. Metabolic Treatment of Cancer: Intermediate Results of a Prospective Case Series . Schwartz L, Buhler L, Icard P, Lincet H, Steyaert JM. Anticancer Research. 2014;34(2):973-80. Lipoic Acid in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review . Liu F, Lv J, Chen Y, et al. Nutrition & Metabolism. 2025;22(1):56. doi:10.1186/s12986-025-00954-9.

How to Diagnose SIBO: A Guide to Current Diagnostic Methods By Yoon Hang Kim MD MPH About Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified integrative medicine physician with over 20 years of clinical experience. He completed his integrative medicine fellowship at the University of Arizona under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture, and integrative/holistic medicine. Through his telemedicine practice, Dr. Kim specializes in utilizing LDN or Low Dose Naltrexone for treating autoimmune conditions, chronic pain, integrative oncology, and complex conditions including fibromyalgia, chronic fatigue, MCAS, and mold toxicity. He is the author of three books and more than 20 articles, and has helped establish integrative medicine programs at institutions nationwide. Professional:   www.yoonhangkim.com  | Clinical:   www.directintegrativecare.com How to Diagnose SIBO: A Guide to Current Diagnostic Methods to SIBO Testing Small intestinal bacterial overgrowth (SIBO) presents a diagnostic challenge that many clinicians encounter regularly. Patients arrive with familiar complaints—bloating, abdominal pain, diarrhea, and signs of malabsorption—yet confirming SIBO requires navigating a landscape of imperfect testing options. This article reviews the diagnostic approaches currently available, their strengths and limitations, and practical considerations for clinical decision-making. Understanding the Diagnostic Challenge SIBO occurs when excessive bacterial populations colonize the small intestine, disrupting normal digestive and absorptive functions. The condition frequently overlaps with irritable bowel syndrome (IBS) and other functional gastrointestinal disorders, making accurate diagnosis essential for targeted treatment (Efremova et al., 2023; Losurdo et al., 2020). No single test offers perfect sensitivity and specificity. Clinicians must therefore understand each method's characteristics to select appropriate testing strategies based on clinical presentation and available resources. Direct Testing: Small Bowel Aspirate and Culture Small bowel aspirate with quantitative culture remains the reference standard for SIBO diagnosis because it directly measures bacterial populations in the small intestine (Maeda & Murakami, 2023). Procedure and Thresholds The technique involves collecting fluid from the duodenum or jejunum during upper endoscopy (Silva et al., 2025). Diagnostic thresholds have evolved over time: Traditional threshold:  >10⁵ CFU/mL Current recommended threshold:  ≥10³ CFU/mL (Rao & Bhagatwala, 2019; Skrzydło-Radomańska & Cukrowska, 2022) The lower threshold reflects growing recognition that clinically significant overgrowth can occur at bacterial concentrations previously considered normal. Limitations Despite its diagnostic precision, small bowel aspirate has significant practical limitations: Invasiveness:  Requires endoscopy with associated costs and patient burden Contamination risk:  Oral and pharyngeal bacteria may contaminate samples during scope passage Sampling bias:  Only evaluates the proximal small bowel, potentially missing distal overgrowth Limited availability:  Not routinely performed at many clinical sites These constraints make direct culture impractical for most clinical scenarios, though it remains valuable for research and complex cases (Rao & Bhagatwala, 2019; Silva et al., 2025). Breath Testing: The Clinical Workhorse Breath testing has become the most widely used diagnostic method due to its non-invasive nature, safety profile, and accessibility (Efremova et al., 2023; Losurdo et al., 2020). The test measures hydrogen and methane gases produced by bacterial fermentation of ingested substrates. Substrate Selection: Glucose vs. Lactulose The choice of substrate significantly influences test performance, and understanding these differences is crucial for interpretation. Glucose Breath Test Rapidly absorbed in the proximal small intestine Higher specificity with fewer false positives May miss distal small bowel overgrowth Better choice when proximal SIBO is suspected Lactulose Breath Test Transits the entire small bowel before colonic fermentation Higher sensitivity for detecting overgrowth Greater risk of false positives due to early colonic arrival Better choice when distal involvement is suspected Clinicians should select substrates based on clinical suspicion regarding the location of overgrowth (Losurdo et al., 2020; Silva et al., 2025). Interpreting Results A positive breath test typically shows an early rise in hydrogen (≥20 ppm above baseline within 90 minutes) or elevated methane levels (≥10 ppm). However, interpretation requires clinical correlation, as breath test accuracy varies considerably across studies. Laboratory Markers: Indirect Evidence Blood and stool tests cannot confirm SIBO directly but provide valuable indirect evidence of its metabolic consequences. Nutritional Deficiencies Bacterial overgrowth impairs nutrient absorption, potentially causing deficiencies in: Vitamin B12:  Bacteria consume B12 before host absorption Iron:  Mucosal inflammation reduces absorption Fat-soluble vitamins (A, D, E):  Bile acid deconjugation impairs fat absorption These deficiencies are more common in severe or longstanding cases (Skrzydło-Radomańska & Cukrowska, 2022). IBS-Smart™ Testing This blood test measures antibodies to cytolethal distending toxin B (anti-CdtB) and vinculin (anti-vinculin). Elevated levels indicate post-infectious IBS, which carries significant risk for SIBO due to associated motility impairment (Takakura & Pimentel, 2020). While not a direct SIBO test, positive results support the diagnosis in appropriate clinical contexts and may guide treatment decisions. Urinary Organic Acids Specialized tests measuring urinary organic acids such as PABA-UDCA disulfate or indican reflect bacterial metabolic activity and can support SIBO diagnosis (Maeda & Murakami, 2023). These tests are less commonly used but may prove helpful in equivocal cases. Structural Assessment: Identifying Predisposing Factors Imaging studies identify anatomical abnormalities that predispose to bacterial stasis and overgrowth. When to Consider Imaging Structural assessment is particularly valuable when clinical history suggests: Prior abdominal surgery with potential blind loop formation Strictures from inflammatory bowel disease or radiation Small bowel diverticula Motility disorders Imaging Modalities CT or MR Enterography High-resolution visualization of small bowel anatomy Identifies strictures, diverticula, and other structural abnormalities Useful for excluding alternative diagnoses (Silva et al., 2025) Barium Contrast Studies Assesses motility patterns Identifies anatomical pockets promoting bacterial stasis Less commonly used but remains valuable in specific scenarios (Skrzydło-Radomańska & Cukrowska, 2022) A Practical Diagnostic Algorithm Given the limitations of available tests, a thoughtful diagnostic approach considers clinical probability, test characteristics, and practical constraints. High Clinical Suspicion + Classic Symptoms → Breath testing (glucose or lactulose based on suspected location) → Consider empiric treatment trial if breath testing unavailable Recurrent or Refractory Cases → Consider small bowel aspirate if available → Structural imaging to identify predisposing factors → IBS-Smart™ testing to evaluate for post-infectious etiology Nutritional Consequences Present → Laboratory assessment for vitamin deficiencies → More aggressive treatment and monitoring warranted Conclusion SIBO diagnosis requires integrating clinical judgment with imperfect diagnostic tools. While small bowel aspirate and culture offers the highest diagnostic certainty, breath testing remains the practical first-line approach for most patients. Laboratory markers and imaging provide complementary information that guides both diagnosis and treatment planning. In some cases, if your symptoms are classic for SIBO, a doctor might skip the testing and prescribe a course of antibiotics (like Rifaximin). If your symptoms significantly improve during the trial, it is often treated as a "functional" diagnosis of SIBO. As research continues to refine diagnostic thresholds and methodologies, clinicians should stay informed about evolving best practices while maintaining focus on the ultimate goal: identifying patients who will benefit from treatment and improving their quality of life. At www.directinegrativecare.com Dr. Kim is dedicated to guiding you on your path to wellness through a deeply personalized and supportive approach. We focus on integrative medicine, looking beyond symptoms to uncover the root causes of chronic conditions and develop a treatment plan tailored specifically to your unique health journey. By combining compassionate care with innovative therapies, our goal is to empower you with the knowledge and tools needed to achieve lasting health. We invite you to explore our website to learn more about how our patient-centered practice can help you find balance and vitality.  Yoon Hang Kim MD Integrative & Functional Medicine Physician Virtual Practice Serving IA, IL, MO, FL, GA, and TX www.directintegrativecare.com References Efremova, I., Maslennikov, R., Poluektova, E., Vasilieva, E., Zharikov, Y., Suslov, A., Letyagina, Y., Kozlov, E., Levshina, A., & Ivashkin, V. (2023). Epidemiology of small intestinal bacterial overgrowth. World Journal of Gastroenterology, 29 (22), 3400–3421. https://doi.org/10.3748/wjg.v29.i22.3400 Losurdo, G., Leandro, G., Ierardi, E., Perri, F., Barone, M., Principi, M., & Di Leo, A. (2020). Breath tests for the non-invasive diagnosis of small intestinal bacterial overgrowth: A systematic review with meta-analysis. Journal of Neurogastroenterology and Motility, 26 (1), 16–28. https://doi.org/10.5056/jnm19113 Maeda, Y., & Murakami, T. (2023). Diagnosis by microbial culture, breath tests and urinary excretion tests, and treatments of small intestinal bacterial overgrowth. Antibiotics, 12 (2), Article 263. https://doi.org/10.3390/antibiotics12020263 Nababan, T., & Fauzi, A. (2015). Diagnosis and treatment of small intestinal bacterial overgrowth. The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy, 16 (2), 105–111. https://doi.org/10.24871/1622015105-111 Rao, S. S. C., & Bhagatwala, J. (2019). Small intestinal bacterial overgrowth: Clinical features and therapeutic management. Clinical and Translational Gastroenterology, 10 (10), Article e00078. https://doi.org/10.14309/ctg.0000000000000078 Silva, B. C. da, Ramos, G. P., Barros, L. L., Ramos, A. F. P., Domingues, G., Chinzon, D., & Passos, M. de C. F. (2025). Diagnosis and treatment of small intestinal bacterial overgrowth: An official position paper from the Brazilian Federation of Gastroenterology. Arquivos de Gastroenterologia, 62 . https://doi.org/10.1590/s0004-2803.24612024-107 Skrzydło-Radomańska, B., & Cukrowska, B. (2022). How to recognize and treat small intestinal bacterial overgrowth? Journal of Clinical Medicine, 11 (20), Article 6017. https://doi.org/10.3390/jcm11206017 Takakura, W., & Pimentel, M. (2020). Small intestinal bacterial overgrowth and irritable bowel syndrome – An update. Frontiers in Psychiatry, 11 , Article 664. https://doi.org/10.3389/fpsyt.2020.00664

Edited by Yoon Hang Kim MD MPH About Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified integrative medicine physician with over 20 years of clinical experience. He completed his integrative medicine fellowship at the University of Arizona under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture, and integrative/holistic medicine. Through his telemedicine practice, Dr. Kim specializes in utilizing LDN or Low Dose Naltrexone for treating autoimmune conditions, chronic pain, integrative oncology, and complex conditions including fibromyalgia, chronic fatigue, MCAS, and mold toxicity. He is the author of three books and more than 20 articles, and has helped establish integrative medicine programs at institutions nationwide. Professional:   www.yoonhangkim.com  | Clinical:   www.directintegrativecare.com Low-Dose Naltrexone (LDN) for Small Intestinal Bacterial Overgrowth (SIBO): An Integrative and Functional Medicine Perspective Telemedicine Low-Dose Naltrexone (LDN) for Small Intestinal Bacterial Overgrowth (SIBO): An Integrative and Functional Medicine Perspective Abstract Small intestinal bacterial overgrowth (SIBO) remains one of the more frustrating conditions in gastroenterology—not because we can't treat it, but because it keeps coming back. Standard antibiotic therapy works, but relapse rates are discouragingly high. That's why many of us in integrative medicine and functional medicine have turned to low-dose naltrexone (LDN) as an adjunctive therapy. This article examines the science behind LDN, the clinical evidence supporting its use in SIBO, and what patients are actually experiencing. While we're still waiting on the randomized controlled trials we'd all like to see, the observational data, expert clinical experience, and patient-reported outcomes are compelling enough that LDN deserves serious consideration for patients with persistent SIBO. Keywords: Integrative Medicine, Functional Medicine, LDN, SIBO, low-dose naltrexone, small intestinal bacterial overgrowth, gut motility, immunomodulation, prokinetic therapy Low-Dose Naltrexone (LDN) for Small Intestinal Bacterial Overgrowth (SIBO): An Integrative and Functional Medicine Perspective Introduction If you've treated SIBO patients, you know the pattern: antibiotics work, symptoms improve, and then—often within weeks—everything returns. Small intestinal bacterial overgrowth affects patients with bloating, abdominal pain, diarrhea or constipation, and nutrient malabsorption (Pimentel et al., 2020). The condition can lead to poor absorption of fats, proteins, carbohydrates, and calcium, raising the risk of complications like osteoporosis. Certain populations face higher SIBO risk. Patients with chronic disease often experience more severe or recurrent symptoms. As we age, stomach acid decreases and motility slows—both risk factors. Previous abdominal surgery and structural abnormalities can impair the normal movement of waste from the small intestine into the large intestine, promoting bacterial buildup. Conventional management relies on antibiotics (typically rifaximin), low-FODMAP diets to limit carbohydrates that feed problematic bacteria, and prokinetic agents to restore motility. The problem? About two-thirds of successfully treated cases relapse within 2.5 months on average (Lauritano et al., 2008). That's why those of us practicing integrative medicine and functional medicine look beyond the standard playbook. We see SIBO as a symptom of deeper imbalances—impaired gut motility, immune dysregulation, intestinal barrier dysfunction, and dysbiosis. Low-dose naltrexone (LDN) addresses several of these underlying issues, which is why it's become an increasingly important tool in our practices. Understanding Low-Dose Naltrexone and Opioid Receptors Naltrexone has been around since 1984, FDA-approved as an opioid antagonist at 50 mg doses for treating alcohol and opioid addiction. Low-dose naltrexone is a different animal entirely. At doses of 0.5 to 4.5 mg—less than 10% of the standard dose—the drug does something unexpected (Younger et al., 2014). Here's how it works: LDN temporarily blocks opioid receptors for about four to six hours. The body responds by ramping up production of endogenous opioids—endorphins and enkephalins—natural peptides that modulate pain, immune function, and cell growth (Arata, 2018). After LDN clears, you're left with elevated endorphin levels for 18 to 20 hours. LDN also modulates toll-like receptor 4 (TLR4) pathways, producing anti-inflammatory and immune-regulating effects (Younger & Mackey, 2009). A few practical points: the typical research dose is 4.5 mg daily. Since no commercial low-dose formulation exists, patients obtain LDN from compounding pharmacies as capsules, sublingual drops, or creams. It's contraindicated with opioid medications. And unlike traditional opioid painkillers, LDN carries no addiction or dependence risk—making it a safer long-term option. Dr. Bernard Bihari pioneered LDN for autoimmune conditions back in 1985, and research has expanded its applications considerably since then. I should be clear: LDN use for SIBO is experimental. There are no formal guidelines or FDA approval for this indication. Our dosing and safety data come primarily from research studies and clinical experience rather than established protocols. That said, the safety profile is favorable, and the mechanistic rationale is sound. The Functional Medicine Approach to LDN in SIBO Those of us trained in functional medicine—whether through the Institute for Functional Medicine, the University of Arizona's integrative medicine fellowship, or similar programs—don't view SIBO as an isolated gut problem. It's a manifestation of interconnected imbalances: compromised motility, immune dysregulation, nutrient malabsorption, and disrupted gut-brain axis signaling. This perspective becomes especially valuable for complex or recurrent cases, particularly patients who also have autoimmune diseases, fibromyalgia, or other chronic inflammatory conditions. LDN fits naturally into this framework. By modulating opioid receptors in the central nervous system, it enhances endogenous opioid production and promotes natural anti-inflammatory effects. It helps regulate immune responses by reducing proinflammatory cytokines—supporting the body's own healing capacity rather than simply suppressing symptoms. In practice, I integrate LDN into comprehensive, individualized protocols. These typically include dietary interventions to reduce fermentable carbohydrates, targeted supplementation with fat-soluble vitamins and bile salts to optimize nutrient absorption, and prokinetic agents to address motility dysfunction. LDN often works alongside herbal antimicrobials and mind-body techniques like meditation. The goal is always to address root causes, not just manage symptoms. Patient education matters here. I spend time explaining why we're using LDN, what realistic expectations look like based on published outcomes, and how we'll adjust dosing based on individual response. This collaborative approach—where patients become active participants in their healing—tends to produce better long-term results for SIBO and related chronic conditions. Mechanisms of LDN Relevant to Small Intestinal Bacterial Overgrowth Several mechanisms make LDN relevant for SIBO. First, it has prokinetic properties—it enhances the migrating motor complex (MMC), the cyclical pattern of gut motility that sweeps bacteria and debris from the small intestine between meals (Siebecker, 2023). When the MMC doesn't function properly, bacteria accumulate. This is arguably the central problem in SIBO, and LDN helps address it. Second, LDN's immunomodulatory effects may tackle the autoimmune component of SIBO. Pimentel's research has shown that post-infectious SIBO involves autoantibodies against vinculin, a protein critical for intestinal nerve function (Pimentel et al., 2015). By modulating T-cell and B-cell activity through opioid growth factor (OGF) receptor interactions, LDN may reduce autoantibody production and help restore normal gut motility. LDN also acts on microglial cells in the central nervous system, decreasing neuroinflammation and downregulating proinflammatory cytokines. This mechanism may affect substance P, a neuropeptide involved in pain signaling—relevant for patients with concurrent fibromyalgia or chronic pain. In fact, LDN may be one of the first glial cell modulators used for chronic pain management. Third, LDN supports intestinal barrier integrity. The "leaky gut" associated with SIBO improves through TLR4-mediated anti-inflammatory effects, which promote mucosal healing and reduce bacterial translocation (Carnahan, 2016). Finally, by reducing the cytokine activation that perpetuates mast cell activation—a common comorbidity in complex SIBO cases—LDN addresses yet another piece of the puzzle. Clinical Evidence and Expert Perspectives Let me be honest about the evidence: we don't have large randomized controlled trials for LDN in SIBO specifically. What we do have is observational data, case series, and substantial expert clinical experience. Research has also explored LDN's benefits in Crohn's disease, multiple sclerosis, rheumatoid arthritis, and as a cancer treatment adjunct. Ploesser et al. (2010) surveyed LDN use in gastrointestinal disorders and found that among patients with IBS and evidence of SIBO, 17.6% reported marked improvement and 37.6% reported moderate benefit. Overall, about 68% showed symptomatic improvement. Patients commonly report better sleep quality, reduced fatigue, improved mood, and increased mobility as pain and inflammation decrease. Dr. Leonard Weinstock, a gastroenterologist at Washington University and medical advisor for the LDN Research Trust, has published extensively on LDN in GI conditions. His 2018 BMJ Case Reports paper documented successful treatment of POTS and mast cell activation syndrome using combined LDN, immunoglobulin, and antibiotics for concurrent SIBO (Weinstock et al., 2018). He's stated publicly that LDN is indispensable in his practice, having prescribed it to thousands of patients. Dr. Allison Siebecker, who specializes in SIBO, includes LDN among her recommended prokinetic options for relapse prevention. It's not technically a prokinetic, but it has prokinetic effects plus additional benefits: immune balancing, inflammation reduction, mood improvement (Siebecker, 2023). Dr. Michael Ruscio uses LDN in his SIBO protocols, particularly for patients with extra-intestinal manifestations like restless leg syndrome, rosacea, and chronic fatigue. When the big names in this field are all using it, that tells you something. Patient Community Perspectives Patient testimonials add real-world context to the clinical data. Many patients with chronic disease or autoimmune conditions seek out LDN hoping to address multiple health concerns simultaneously. The LDN Research Trust has documented numerous patient stories where individuals report expanded dietary tolerance, reduced joint pain, and return to normal activities after years of SIBO-related restrictions (LDN Research Trust, 2023). One patient described finally being able to "expand her diet and return to regular exercise, removing the joint pain" that had plagued her. In Weinstock's 2018 case report, a patient with severe POTS, MCAS, and SIBO wrote: "I feel like I won the lottery last year by discovering LDN, IVIg and SIBO treatment. LDN made me feel noticeably happier, more energetic, in less pain and with better digestion." Online forums like Health Rising and the Low Toxin Forum feature ongoing discussions about LDN for SIBO. Users share experiences of improved motility, reduced bloating, and better energy. A common theme: LDN requires gradual titration, and some patients do best at doses below the standard 4.5 mg target. These reports align with what I see clinically. Individualized dosing matters. Combination protocols—LDN plus dietary interventions, antimicrobials, and other prokinetics—tend to work better than any single intervention alone. Clinical Application of LDN in SIBO In my practice, I typically start LDN at 0.5 to 1.5 mg at bedtime, titrating gradually over two to four weeks toward 4.5 mg based on tolerance (Weinstock, 2018). Some patients do better at lower maintenance doses—another reason individualized care matters. I often combine LDN with conventional prokinetics like low-dose erythromycin or prucalopride, herbal prokinetics such as ginger and Iberogast, rifaximin or herbal antimicrobials for bacterial reduction, and dietary interventions including low-FODMAP or elemental diets. Side effects are generally mild: vivid dreams, insomnia, headaches, and occasionally GI upset. About 10-15% of patients experience insomnia, which often resolves with morning dosing instead. The absolute contraindication is concurrent opioid use—LDN will precipitate withdrawal. The key point I emphasize with patients: LDN is one component of comprehensive SIBO management, not a standalone cure. We're always addressing underlying causes—motility dysfunction, dietary triggers, immune dysregulation. Conclusion Low-dose naltrexone offers something we don't often see: a single intervention that addresses multiple SIBO-related mechanisms. Prokinetic effects, immunomodulation, anti-inflammatory activity, intestinal barrier support—it's a multitasker with a favorable safety profile. The evidence base isn't where we'd like it to be; we need randomized controlled trials specifically examining LDN for SIBO eradication and relapse prevention. Until that research arrives, LDN remains a reasonable consideration for treatment-resistant SIBO, especially in patients with comorbid conditions like mast cell activation syndrome, POTS, or autoimmune features. We should counsel patients about off-label use while acknowledging what clinical experience consistently shows: for many patients, LDN makes a meaningful difference. In integrative medicine and functional medicine, that's often enough to warrant a thoughtful trial. Low-Dose Naltrexone (LDN) for Small Intestinal Bacterial Overgrowth (SIBO): An Integrative and Functional Medicine Perspective About Dr. Kim's Telemedicine Practice At www.directintegrativecare.com , Dr. Kim is dedicated to guiding you on your path to wellness through a deeply personalized and supportive approach. We focus on integrative medicine, looking beyond symptoms to uncover the root causes of chronic conditions and develop a treatment plan tailored specifically to your unique health journey. By combining compassionate care with innovative therapies, our goal is to empower you with the knowledge and tools needed to achieve lasting health. We invite you to explore our website to learn more about how our patient-centered practice can help you find balance and vitality.  Yoon Hang Kim MD Integrative & Functional Medicine Physician www.directintegrativecare.com Meet Dr. Kim - Yoon Hang Kim MD MPH Integrative Medicine, Functional Medicine, Metabolic Medicine Expert and LDN Authority References Arata, M. (2018). Low dose naltrexone (LDN) and small intestinal bacterial overgrowth (SIBO)  [Conference presentation]. LDN Research Trust Conference. Carnahan, J. C. (2016). Low dose naltrexone (LDN): The treatment you've never heard of. International Journal of Complementary & Alternative Medicine, 4 (3), 00123. https://doi.org/10.15406/ijcam.2016.04.00123 Lauritano, E. C., Gabrielli, M., Scarpellini, E., Lupascu, A., Novi, M., Sottili, S., ... & Gasbarrini, A. (2008). Small intestinal bacterial overgrowth recurrence after antibiotic therapy. American Journal of Gastroenterology, 103 (8), 2031-2035. LDN Research Trust. (2023). Patient testimonials and resources.   https://ldnresearchtrust.org Pimentel, M., Saad, R. J., Long, M. D., & Rao, S. S. C. (2020). ACG clinical guideline: Small intestinal bacterial overgrowth. American Journal of Gastroenterology, 115 (2), 165-178. https://doi.org/10.14309/ajg.0000000000000501 Pimentel, M., Morales, W., Pokkunuri, V., Brikos, C., Kim, S. M., Kim, S. E., ... & Chang, C. (2015). Autoimmunity links vinculin to the pathophysiology of chronic functional bowel changes following Campylobacter jejuni  infection in a rat model. Digestive Diseases and Sciences, 60 (5), 1195-1205. Ploesser, J., Weinstock, L. B., & Thomas, E. (2010). Low dose naltrexone: Effects on medication in chronic pain and fatigue syndromes. International Journal of Pharmaceutical Compounding, 14 (5), 360-364. Siebecker, A. (2023). Prevention of SIBO relapse.  SIBO Info. https://www.siboinfo.com/prevention-of-relapse.html Weinstock, L. B., Brook, J. B., Myers, T. L., & Goodman, B. (2018). Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment. BMJ Case Reports, 2018 , bcr-2017-221405. https://doi.org/10.1136/bcr-2017-221405 Younger, J., & Mackey, S. (2009). Fibromyalgia symptoms are reduced by low-dose naltrexone: A pilot study. Pain Medicine, 10 (4), 663-672. Younger, J., Parkitny, L., & McLain, D. (2014). The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clinical Rheumatology, 33 (4), 451-459. https://doi.org/10.1007/s10067-014-2517-2 Disclaimer This article provides an evidence-informed overview of low-dose naltrexone for SIBO within integrative and functional medicine frameworks. The information presented is for educational purposes only and does not constitute medical advice. Readers should consult qualified healthcare professionals for personalized treatment decisions. LDN use for SIBO is considered off-label and should be prescribed and monitored by appropriately trained clinicians.

An Evidence-Based Overview of Eurycoma longifolia (Tongkat Ali): Effects on Testosterone Levels and Prostate Health - Integrative Functional Medicine Edited by Yoon Hang Kim, MD, MPH Dr. Yoon Hang “John” Kim, a recipient of the 2024 Functional Medicine for All scholarship from the Institute for Functional Medicine, brings over 20 years of experience in integrative and functional medicine to his telemedicine practice. After serving as chief wellness officer at a community hospital in Carthage, IL—where he provided care to rural and underserved populations—Dr. Kim now offers virtual integrative and functional medicine services, making personalized, evidence-based care accessible regardless of location. His clinical approach integrates functional medicine laboratory testing with complementary therapies, including meditation, yoga, tai chi, and lifestyle interventions that use food and physical activity as medicine to address root causes of disease. Dr. Kim earned his medical degree from the Medical College of Wisconsin, completed a Master of Public Health at San Diego State University, and trained with Dr. Andrew Weil during his residential fellowship at the University of Arizona. Board-certified by the American Board of Preventive Medicine, the American Board of Medical Acupuncture, and the American Board of Integrative and Holistic Medicine, Dr. Kim has served as a faculty member, consultant, and founder of the Integrative Health Studies Certificate program at the University of West Georgia. His clinical interests include autoimmune disease, chronic pain, integrative oncology, and gastrointestinal disorders. He specializes in complex conditions such as fibromyalgia, chronic fatigue syndrome, long COVID, and toxic mold illness. Dr. Kim has authored two books and more than 20 peer-reviewed and professional articles and has helped establish integrative medicine programs across multiple institutions. Professional Inquiries: www.yoonhangkim.com Clinical Inquiries: www.directintegrativecare.com Introduction to Eurycoma longifolia Eurycoma longifolia Jack, commonly known as Tongkat Ali or Longjack, is a traditional Southeast Asian medicinal herb derived from the roots of a shrub native to Malaysia and Indonesia. It has gained increasing scientific interest for its potential to enhance male vitality, primarily through modulation of testosterone levels. This article reviews the current evidence regarding Eurycoma longifolia’s effects on serum testosterone and prostate health, drawing from randomized controlled trials (RCTs), systematic reviews and meta-analyses, and preclinical studies. Clinical Evidence on Testosterone Enhancement A growing body of clinical research supports the ability of Eurycoma longifolia supplementation to increase serum testosterone, particularly in men with hypogonadism or age-related androgen decline. However, interpretation of this evidence requires attention to methodological limitations. Systematic Review and Meta-Analysis Evidence A 2022 systematic review and meta-analysis by Leisegang et al. evaluated nine studies, five of which were included in the quantitative meta-analysis. The pooled analysis demonstrated a statistically significant increase in total testosterone, with a standardized mean difference (SMD) of 1.352 (95% CI: 0.565–2.138; p = 0.001). The effect was most pronounced in hypogonadal men, though benefits were also observed in eugonadal individuals. Subgroup analysis revealed greater improvements among participants with low baseline testosterone levels. Methodological Considerations Several important limitations must be acknowledged: Publication bias: Begg’s test indicated significant publication bias (p = 0.0243), with additional bias detected in the hypogonadal subgroup using Egger’s and Begg’s tests, suggesting overrepresentation of positive findings. Industry involvement: Seven of the nine studies utilized Physta®, a proprietary extract produced by Biotropics Malaysia Berhad. Several trials were industry-funded, and some authors were company employees. While not invalidating the results, this represents a potential conflict of interest. Heterogeneity: Substantial heterogeneity was observed across studies (I² = 87.27%), reflecting variability in study populations, dosing, duration, and outcome measures. Key Individual Clinical Trials Chinnappan et al. (2021): A multicenter, double-blind, placebo-controlled RCT involving 105 men aged 50–70 years with baseline testosterone <300 ng/dL found that daily supplementation with 100 mg or 200 mg of a standardized aqueous extract (Physta®) for 12 weeks significantly increased total testosterone. The 200 mg dose produced earlier and stronger effects, with significance observed as early as week 4. Quality-of-life scores also improved. This study was funded by Biotropics Malaysia Berhad, and two authors were company employees. Leitão et al. (2021): In a six-month RCT involving 45 men with androgen deficiency of aging males (ADAM), 200 mg/day of Eurycoma longifolia combined with concurrent training significantly improved erectile function and increased total testosterone. Approximately 50% of participants demonstrated testosterone increases, with the greatest benefits observed in the combined exercise and supplementation group. Chan et al. (2021): In a study of 32 healthy young men (mean age 24), supplementation with 600 mg/day for two weeks increased total testosterone by 15% and free testosterone by 34% compared with placebo. Luteinizing hormone and follicle-stimulating hormone levels did not change, suggesting a mechanism independent of direct hypothalamic-pituitary-gonadal axis stimulation. The hypothalamic-pituitary-adrenal axis has been proposed but remains speculative. Collectively, these studies suggest that doses of 200–600 mg/day of standardized extracts (typically containing 0.8–1.5% eurycomanone) administered for 2–12 weeks may increase testosterone levels, with potential benefits for energy, libido, and muscle strength. Individual response variability remains substantial. Clinical Evidence on Prostate Health Direct human clinical evidence evaluating Eurycoma longifolia’s effects on prostate health outcomes—such as benign prostatic hyperplasia (BPH), prostate volume, prostate-specific antigen (PSA), or prostate cancer risk—is limited. No large-scale RCTs have specifically assessed prostate-related endpoints. Preclinical Evidence Preclinical findings offer mixed insights. In vitro studies of quassinoids such as eurycomanone demonstrate anti-proliferative and pro-apoptotic effects in prostate cancer cell lines. Tong et al. (2015) reported that a standardized quassinoid composition (SQ40) inhibited LNCaP prostate cancer cell growth via G0/G1 cell cycle arrest, apoptosis induction, reduced androgen receptor translocation, and decreased PSA secretion. In mouse xenograft models, SQ40 significantly suppressed tumor growth. Animal models of testosterone-induced BPH have shown reduced prostate weight and improved histopathology with certain extracts. However, other rodent studies raise concerns that high doses may induce prostatic epithelial proliferation and dysplastic changes, potentially mediated by elevated testosterone levels. No human studies have reported increased PSA levels or prostate cancer incidence associated with Eurycoma longifolia use. Nonetheless, due to its androgen-enhancing effects, caution is generally advised in individuals with known prostate disease. Many clinical guidelines contraindicate its use in active prostate cancer. Safety and Tolerability Clinical trials report good tolerability at doses ranging from 100–600 mg/day, with no significant adverse effects on liver, kidney, or prostate markers over study durations of 2–24 weeks. Reported side effects have been mild and infrequent, including gastrointestinal discomfort and pruritus. Long-term safety data in humans remain limited. Medical supervision is recommended for individuals with hormonal sensitivities, prostate disorders, or those taking medications that may interact with androgenic compounds. Conclusion Eurycoma longifolia (Tongkat Ali): Effects on Testosterone Levels and Prostate Health - Integrative Functional Medicine Current evidence suggests that Eurycoma longifolia may be an effective natural agent for increasing testosterone levels, supported by multiple RCTs and a recent meta-analysis. However, the evidence base has important limitations, including significant publication bias, substantial industry involvement, high heterogeneity, and relatively small sample sizes. Its role in prostate health remains unclear. While preclinical data suggest potential anti-cancer activity, theoretical risks related to androgen elevation warrant caution. Well-designed, independently funded, long-term human studies are needed to clarify both efficacy and prostate-specific safety outcomes. Evidence Quality Assessment Strengths Multiple double-blind, placebo-controlled RCTs Statistically significant pooled effect in meta-analysis (SMD = 1.352) Consistent testosterone increases in hypogonadal and eugonadal men Favorable short-term safety profile Limitations Significant publication bias (p = 0.0243) Heavy reliance on a single proprietary extract High inter-study heterogeneity (I² = 87.27%) Limited long-term safety data Absence of large prostate-specific clinical trials At Direct Integrative Care, Dr. Kim provides personalized, patient-centered integrative medicine focused on identifying root causes and restoring balance. Through compassionate care and evidence-based therapies, patients are empowered with the knowledge and tools needed for sustainable health and vitality. Yoon Hang Kim, MD Integrative & Functional Medicine Physician Virtual Practice Serving IA, IL, MO, FL, GA, and TX www.directintegrativecare.com References References Chan, K. Q., Stewart, C., Chester, N., Hamzah, S. H., & Yusof, A. (2021). The effect of Eurycoma longifolia on the regulation of reproductive hormones in young males. Andrologia, 53 (4), e14001. https://doi.org/10.1111/and.14001 Chinnappan, S. M., George, A., Pandey, P., Narke, G., & Choudhary, Y. K. (2021). Effect of Eurycoma longifolia standardised aqueous root extract–Physta® on testosterone levels and quality of life in ageing male subjects: A randomised, double-blind, placebo-controlled multicentre study. Food & Nutrition Research, 65 , Article 5647. https://doi.org/10.29219/fnr.v65.5647 Leitão, A. E., Vieira, M. C. S., Pelegrini, A., da Silva, E. L., & Guimarães, A. C. A. (2021). A 6-month, double-blind, placebo-controlled, randomized trial to evaluate the effect of Eurycoma longifolia (Tongkat Ali) and concurrent training on erectile function and testosterone levels in androgen deficiency of aging males (ADAM). Maturitas, 145 , 78–85. https://doi.org/10.1016/j.maturitas.2020.12.002 Leisegang, K., Finelli, R., Sikka, S. C., & Panner Selvam, M. K. (2022). Eurycoma longifolia (Jack) improves serum total testosterone in men: A systematic review and meta-analysis of clinical trials. Medicina, 58 (8), Article 1047. https://doi.org/10.3390/medicina58081047 Tong, K. L., Chan, K. L., AbuBakar, S., Low, B. S., Ma, H. Q., & Wong, P. F. (2015). The in vitro and in vivo anti-cancer activities of a standardized quassinoids composition from Eurycoma longifolia on LNCaP human prostate cancer cells. PLOS ONE, 10 (3), e0121752. https://doi.org/10.1371/journal.pone.0121752

Low Dose Naltrexone (LDN) for Lyme Disease: An Integrative Medicine Perspective Yoon Hang "John" Kim, MD, MPH Board-Certified Integrative Medicine Physician Direct Integrative Care Keywords: Low Dose Naltrexone, LDN, Lyme Disease, Post-Treatment Lyme Disease Syndrome, Integrative Medicine, Functional Medicine, Chronic Inflammation, Immunomodulation Low Dose Naltrexone (LDN) for Lyme Disease: About the Author Dr. Yoon Hang "John" Kim, residential fellowship trained in integrative medicine at University of Arizona and a recipient of the 2024 Functional Medicine for All scholarship from the Institute for Functional Medicine, brings over 20 years of experience in integrative and functional medicine to his telemedicine practice. After serving as chief wellness officer at a community hospital in Carthage, IL, where he provided care to rural and underserved populations, Dr. Kim now offers virtual integrative and functional medicine services, making personalized, evidence-based care accessible to patients regardless of location. His approach combines functional medicine lab testing with complementary therapies such as meditation, yoga, tai chi, and lifestyle interventions using food and physical activity as medicine, addressing the root causes of disease. Dr. Kim earned his medical degree from the Medical College of Wisconsin, completed a master’s in public health at San Diego State University, and trained with Dr. Andrew Weil during his residential fellowship at the University of Arizona. Certified by the American Board of Preventive Medicine, the American Board of Medical Acupuncture, and the American Board of Integrative and Holistic Medicine, he has also contributed to the field as a faculty member, consultant, and founder of the Integrative Health Studies Certificate program at the University of West Georgia. With clinical interests in autoimmune conditions, chronic pain, integrative oncology, and gastrointestinal disorders, Dr. Kim specializes in treating complex conditions such as fibromyalgia, chronic fatigue syndrome, long COVID symptoms, and toxic mold illness, and has authored two books and over 20 articles while helping establish integrative medicine practices across various institutions. Professional Inquiries:   www.yoonhangkim.com Clinical Inquiries:   www.directintegrativecare.com Why I Started Using LDN for My Lyme Patients If you're reading this, chances are you or someone you love is struggling with Lyme disease—and you're searching for answers beyond the conventional playbook. I get it. After two decades of practicing integrative medicine and seeing thousands of patients with complex chronic illness, I've learned that Lyme rarely plays by the rules. Here's what frustrates me: Lyme disease is now the most common vector-borne illness in North America, yet so many patients feel abandoned by the healthcare system. They get their round of antibiotics, and when symptoms persist—the crushing fatigue, the brain fog, the joint pain that just won't quit—they're often told it's "all in their head." It's not. And that's exactly why I turned to LDN as part of my functional medicine approach. Low Dose Naltrexone, or LDN, has become one of my go-to tools for patients dealing with the aftermath of Lyme. It's not a magic bullet—nothing is—but for the right patient, it can be a game-changer. Let me walk you through what we know, what we're still learning, and how I use it in my integrative medicine practice. First, Let's Talk About What We're Really Dealing With Lyme disease starts simply enough: a tick bite, often unnoticed, delivers Borrelia burgdorferi bacteria into your system. If you're lucky, you spot that classic bull's-eye rash—the erythema migrans that practically screams "Lyme!" You get treated early, and you're fine. But here's the reality I see in my practice: many of my Lyme patients never saw a rash. Or they did see it, got antibiotics, and still ended up sick months later. Research from Johns Hopkins tells us that roughly 10-20% of properly treated Lyme patients develop what we call Post-Treatment Lyme Disease Syndrome, or PTLDS (1,2). That's a lot of people left suffering. These folks aren't making it up. They're dealing with real, measurable inflammation. Studies show elevated cytokines like IL-6, TNF-alpha, and IL-23 in PTLDS patients (5,6). Their immune systems are stuck in overdrive, and that's where functional medicine—and LDN—can really shine. So What Exactly is LDN? Here's where it gets interesting. Naltrexone has been around since the 1980s as a treatment for opioid and alcohol addiction—at doses of 50-100mg. But back in 1985, a brilliant physician named Dr. Bernard Bihari discovered something unexpected: at much lower doses (we're talking 0.1-4.5mg), naltrexone does something completely different. Instead of just blocking opioid receptors, it actually helps regulate the immune system (9). Think of it this way: when you take LDN at bedtime, it briefly blocks your opioid receptors for about 4-6 hours. Your body responds by ramping up production of endorphins—your natural feel-good, immune-regulating molecules. By morning, you've got more endorphins on board, and your immune system has gotten a gentle nudge toward balance (10). This is exactly the kind of approach we embrace in integrative medicine: working with your body's own healing mechanisms rather than against them. How LDN Actually Helps Lyme Patients When I explain LDN to my Lyme patients, I focus on four key mechanisms. Understanding these helps you appreciate why this humble medication can make such a difference. It Calms Down Overactive Immune Signaling One of the most exciting discoveries about LDN is its ability to quiet down something called Toll-Like Receptor 4, or TLR4. This receptor is like an alarm system on your immune cells—helpful when there's a real threat, but problematic when it won't stop ringing. In chronic Lyme, that alarm often stays stuck in the "on" position, pumping out inflammatory signals. LDN helps turn down the volume (11,12). It Addresses Brain Inflammation If you've got "Lyme brain"—that awful fog where you can't find words or remember why you walked into a room—this one's for you. LDN modulates microglial cells, the immune cells in your brain. It helps shift them from an angry, inflammatory state to a calmer, more supportive one (13,14). Many of my patients notice improved mental clarity within weeks of starting LDN. It Rebalances Your Immune System Chronic Lyme often throws the immune system out of whack—too much activity in some areas, not enough in others. In functional medicine terms, we see imbalances in Th1/Th2 responses and overactive Th17 pathways. LDN helps restore equilibrium, which is exactly what we're aiming for when we take an integrative medicine approach to complex illness (15). It Boosts Your Body's Natural Painkillers Remember that endorphin boost I mentioned? That translates to real-world pain relief for many patients. Unlike conventional pain medications that can create dependency and have significant side effects, LDN works by enhancing what your body already produces (16). What Does the Research Actually Show? I'll be honest with you—and this is important if you're doing your own research—we don't yet have randomized controlled trials specifically looking at LDN for Lyme disease. What we do have is compelling clinical experience and solid evidence from related conditions. Dr. Richard Horowitz, who's treated over 12,000 Lyme patients, shared his experience at the 2012 Integrative Healthcare Symposium. In his practice, about 75% of Lyme patients experienced meaningful improvement in fatigue, muscle pain, and joint discomfort when taking LDN (17). That's a remarkable response rate for a medication with such a favorable safety profile. We also have good data from fibromyalgia, which shares many features with chronic Lyme. A Stanford University trial found that LDN reduced pain by nearly 29% compared to 18% with placebo—and half the patients were rated as "much improved" or "very much improved" (18). A 2024 meta-analysis confirmed these findings across multiple trials (19). For me as a functional medicine practitioner, this evidence—combined with what I see every day in my practice—makes LDN a valuable tool in managing chronic Lyme. How I Use LDN in My Integrative Medicine Practice Choosing the Right Patients Not everyone with Lyme needs LDN, and it's not my first-line treatment for acute infection. Where LDN really shines is for patients who've completed appropriate antibiotic therapy but still feel lousy, folks struggling with persistent fatigue, brain fog, and widespread pain, patients with signs of immune dysregulation or autoimmune features, and those who want to reduce their reliance on conventional pain medications. Starting Low and Going Slow Since LDN isn't available commercially in low doses, you'll need a compounding pharmacy. I typically start patients at just 0.5-1mg at bedtime and increase by 0.5mg every week or two. Most people end up somewhere between 3-4.5mg. This gradual approach minimizes side effects and helps us find your sweet spot (21). If you experience vivid dreams or trouble sleeping—the most common early side effects—we can switch to morning dosing. These issues usually fade within a few weeks. The Bigger Picture: A Functional Medicine Approach Here's something I tell every Lyme patient: LDN is a tool, not a complete solution. True healing from chronic Lyme requires addressing the whole picture. In my integrative medicine practice, that means looking at your diet (anti-inflammatory eating is crucial), supporting detoxification pathways, addressing any co-infections, optimizing sleep, managing stress, and supporting mitochondrial function. Dr. Horowitz calls this the "16-point map" approach, and it resonates deeply with how we practice functional medicine. You can't just treat one piece of the puzzle and expect everything to fall into place (23). A Few Important Cautions I want to be straight with you about the limitations. We need more research—specifically, randomized trials in Lyme patients. While the evidence from clinical experience and related conditions is encouraging, it's not the same as having definitive proof. Also, not everyone responds to LDN. In my experience, about 60-75% of patients see meaningful benefit. For the others, we need to keep exploring different approaches. And critically: if you're currently taking opioid medications, you cannot start LDN without an appropriate washout period. LDN will precipitate withdrawal, which is dangerous and extremely unpleasant. Always work with a knowledgeable healthcare provider (22). The Bottom Line After twenty years of practicing integrative medicine and specializing in LDN therapy, I've seen this medication change lives for many Lyme patients. It's safe, it's affordable (typically $30-50 per month from a compounding pharmacy), and it works with your body's own healing mechanisms. Is it right for everyone? No. Is it a standalone cure? Absolutely not. But as part of a comprehensive functional medicine approach to chronic Lyme, LDN deserves serious consideration—especially for those who've tried everything else without success. If you're struggling with persistent Lyme symptoms and wondering whether LDN might help, I encourage you to find an integrative medicine practitioner who understands both Lyme disease and LDN therapy. You deserve a partner who will look at the whole picture and work with you toward real healing. That's what functional medicine is all about—and that's why I love what I do. Meet Dr. Yoon Hang Kim MD Integrative and Functional Medicine Expert and LDN Authority At Direct Integrative Care, Dr. Kim is dedicated to guiding you on your path to wellness through a deeply personalized and supportive approach. We focus on integrative medicine, looking beyond symptoms to uncover the root causes of chronic conditions and develop a treatment plan tailored specifically to your unique health journey. By combining compassionate care with innovative therapies, our goal is to empower you with the knowledge and tools needed to achieve lasting health. We invite you to explore our website to learn more about how our patient-centered practice can help you find balance and vitality.  Yoon Hang Kim MD Integrative & Functional Medicine Physician Virtual Practice Serving IA, IL, MO, FL, GA, and TX www.directintegrativecare.com References 1. Aucott JN, Rebman AW, Crowder LA, Kortte KB. Post-treatment Lyme disease syndrome symptomatology and the impact on life functioning: is there something here? Qual Life Res. 2013;22(1):75-84. 2. Steere AC, Strle F, Wormser GP, et al. Lyme borreliosis. Nat Rev Dis Primers. 2016;2:16090. 5. Soloski MJ, Crowder LA, Lahey LJ, et al. Serum inflammatory mediators as markers of human Lyme disease activity. PLoS One. 2014;9(4):e93243. 6. Aucott JN, Soloski MJ, Rebman AW, et al. CCL19 as a Chemokine Risk Factor for Posttreatment Lyme Disease Syndrome. Clin Vaccine Immunol. 2016;23(9):757-766. 9. Bihari B. Bernard Bihari, MD: low-dose naltrexone for normalizing immune system function. Altern Ther Health Med. 2013;19(2):56-65. 10. Zagon IS, McLaughlin PJ. Opioid growth factor and the treatment of human pancreatic cancer: a review. World J Gastroenterol. 2014;20(9):2218-2223. 11. Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451-459. 12. Cant R, Dalgleish AG, Allen RL. Naltrexone Inhibits IL-6 and TNFα Production in Human Immune Cell Subsets. Front Immunol. 2017;8:809. 13. Parkitny L, Younger J. Reduced Pro-Inflammatory Cytokines after Eight Weeks of Low-Dose Naltrexone for Fibromyalgia. Biomedicines. 2017;5(2):16. 14. Kui N, Raki V, Verko R, et al. Immunometabolic Modulatory Role of Naltrexone in BV-2 Microglia Cells. Int J Mol Sci. 2021;22(16):8429. 15. Tichauer C. LDN and Lyme Disease II. Presented at: LDN Research Trust 2017 Conference; 2017. 16. Zagon IS, McLaughlin PJ. Endogenous opioids and the growth regulation of a neural tumor. Life Sci. 1988;43(16):1313-1318. 17. 2012 Integrative Healthcare Symposium: Treating the Pain of Lyme Disease. P T. 2012;37(4):247-249. 18. Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia. Arthritis Rheum. 2013;65(2):529-538. 19. Arbi NS, et al. Efficacy and safety of low-dose naltrexone for fibromyalgia: a systematic review and meta-analysis. Korean J Pain. 2024;37(4):339-352. 21. Elsegood L. The LDN Book. Chelsea Green Publishing; 2016. 22. Li Z, You Y, Griffin N, et al. Low-dose naltrexone (LDN): A promising treatment in immune-related diseases. Int Immunopharmacol. 2018;61:178-184. 23. Horowitz RI. Why Can't I Get Better? Solving the Mystery of Lyme and Chronic Disease. St. Martin's Press; 2013. Disclaimer: This article is for educational purposes only and does not constitute medical advice. Low-dose naltrexone is not FDA-approved for Lyme disease. Always consult with a qualified healthcare provider before starting any new treatment.

Yoon Hang "John" Kim, MD, MPH Low-Dose Naltrexone LDN in Multiple Sclerosis: An Integrative Medicine Functional Medicine Perspective Low-Dose Naltrexone in Multiple Sclerosis: An Integrative Medicine Perspective About Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified integrative medicine physician with over 20 years of clinical experience. He completed his integrative medicine fellowship at the University of Arizona under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture, and integrative/holistic medicine. Through his telemedicine practice, Dr. Kim specializes in utilizing LDN or Low Dose Naltrexone for treating autoimmune conditions, chronic pain, integrative oncology, and complex conditions including fibromyalgia, chronic fatigue, MCAS, and mold toxicity. He is the author of three books and more than 20 articles, and has helped establish integrative medicine programs at institutions nationwide. Professional:   www.yoonhangkim.com  | Clinical:   www.directintegrativecare.com LDN MS Integrative Medicine Functional Medicine Introduction Multiple sclerosis (MS) remains one of the most challenging autoimmune disorders affecting the central nervous system, characterized by chronic inflammation, progressive demyelination, and cumulative neurological disability. For the estimated 2.8 million people living with MS worldwide, the journey involves navigating complex treatment decisions, managing unpredictable symptoms, and maintaining quality of life despite disease progression (Walton et al., 2020). While conventional disease-modifying therapies (DMTs) form the cornerstone of MS management, many patients and practitioners within integrative medicine and functional medicine are exploring complementary approaches that address the multifaceted nature of this condition. Low-dose naltrexone (LDN), typically administered at 0.5 to 4.5 mg nightly, has emerged as one such option garnering significant attention. Originally developed at standard doses (50 mg) for opioid and alcohol dependence, naltrexone at low doses appears to exert fundamentally different pharmacological effects—shifting from sustained opioid receptor blockade to transient receptor modulation with potential immunomodulatory consequences. This article examines the current evidence base for LDN in MS, explores proposed mechanisms of action, and contextualizes its role within a comprehensive integrative medicine framework. Understanding Low-Dose Naltrexone: Mechanisms and Rationale The therapeutic rationale for LDN diverges substantially from its parent compound's original application. At standard doses, naltrexone provides continuous opioid receptor antagonism lasting approximately 24 hours. In contrast, low-dose naltrexone at 4.5 mg produces a brief blockade lasting only 4 to 6 hours, typically during sleep. This transient blockade triggers a compensatory upregulation of endogenous opioid production—including beta-endorphin and met-enkephalin—and may increase opioid receptor sensitivity (Brown & Panksepp, 2009). This interaction with opioid receptors also influences immune system balance, as LDN's effects on opioid pathways can modulate inflammatory responses. From a functional medicine perspective, this mechanism is particularly relevant. Endogenous opioids play crucial roles in immune regulation, with beta-endorphin affecting natural killer cell activity, T-lymphocyte proliferation, and inflammatory cytokine production. The endorphin hypothesis suggests that many autoimmune conditions, including MS, may involve relative deficiencies in endogenous opioid tone, contributing to immune dysregulation and chronic inflammation (Zagon & McLaughlin, 2017). Additionally, LDN appears to modulate glial cell activity within the central nervous system. Microglia and astrocytes, when chronically activated, contribute substantially to neuroinflammation and may perpetuate the inflammatory cascade seen in MS. Research suggests that LDN may attenuate this glial activation, potentially reducing the production of pro-inflammatory cytokines and neurotoxic mediators (Younger & Mackey, 2014). This dual action—peripheral immune modulation combined with central nervous system effects—aligns well with integrative medicine approaches that seek to address disease processes at multiple levels simultaneously. Clinical Evidence: What the Research Demonstrates Randomized Controlled Trials The clinical investigation of LDN in MS, while still evolving, has produced several noteworthy studies. Cree et al. (2010) conducted a pilot crossover trial examining 4.5 mg LDN in 80 patients with clinically definite MS over an 8-week period. Despite some attrition affecting statistical power, the study yielded important findings: LDN demonstrated excellent tolerability with no serious adverse events, and participants showed significant improvements in mental health-related quality of life measures. Specifically, improvements were documented in the SF-36 Mental Component Summary and the Perceived Deficits Questionnaire, suggesting potential benefits for cognitive and psychological well-being—domains that significantly impact daily functioning. A subsequent trial by Sharafaddinzadeh et al. (2010) employed a 17-week crossover design in 96 patients with relapsing-remitting or secondary progressive MS. While confirming LDN's favorable safety profile, this study found limited benefit across most quality of life domains. However, a modest improvement in health perception scores emerged, prompting the investigators to recommend longer-duration studies. Gironi et al. (2008) specifically examined LDN in primary progressive MS (PPMS), a subtype historically resistant to many interventions. Their Phase II pilot trial followed 40 patients over six months, demonstrating safety and tolerability alongside intriguing secondary findings: significant reduction in spasticity and elevated beta-endorphin levels, providing some mechanistic validation for the endorphin hypothesis. These results hold particular relevance for integrative medicine practitioners, as spasticity management represents a significant unmet need in progressive MS. Beyond MS, LDN has been studied in other autoimmune and inflammatory conditions. Research in Crohn's disease has shown clinical improvement in active disease, and studies in fibromyalgia and rheumatoid arthritis suggest LDN may help modulate immune responses. These findings support LDN as a potential adjunctive option for various chronic inflammatory conditions. Long-Term Observational Data Observational studies provide insights into real-world effectiveness and long-term outcomes. Ludwig et al. (2016) conducted a 10-year retrospective review of patients treated with LDN, either as monotherapy or adjunctively with glatiramer acetate. Participants demonstrated stable health outcomes without exacerbation of symptoms or significant MRI changes over this extended period. The authors characterized the regimen as safe, non-toxic, and cost-effective—attributes particularly valued within functional medicine practice. A pharmacoepidemiological analysis by Raknes et al. (2017) examined medication patterns among 341 Norwegian MS patients following LDN initiation. The study found no reduction in the use of standard DMTs or symptomatic medications after starting LDN, suggesting that patients and physicians viewed LDN as complementary rather than as a replacement for conventional therapies. This observation aligns with the integrative medicine philosophy of combining evidence-based conventional treatments with complementary approaches. Positioning LDN Within an Integrative Medicine Framework For practitioners of integrative medicine and functional medicine, LDN represents one component within a comprehensive approach to MS management. Rather than viewing it as an alternative to conventional DMTs, LDN may be most appropriately considered as an adjunctive therapy targeting specific symptomatic domains—particularly quality of life, mental health, fatigue, and spasticity—where conventional options may fall short. The functional medicine model emphasizes identifying root causes of disease, supporting the body's inherent healing mechanisms, and personalizing treatment. LDN fits within this framework through its proposed action on endogenous regulatory systems rather than through direct immunosuppression. By potentially restoring opioid system balance and modulating neuroinflammation, LDN may support the body's own regulatory capacity—a principle central to functional medicine philosophy. A comprehensive integrative approach to MS often includes dietary modifications, stress management, physical activity, and addressing environmental factors—all of which can support medical treatments and improve overall wellness. LDN can be one element within this broader therapeutic strategy. From a practical standpoint, LDN offers several advantages: it is generally well-tolerated, relatively inexpensive (typically $35–70 monthly from compounding pharmacies), does not require monitoring bloodwork, and appears to have minimal drug interactions with most MS medications. Common side effects—vivid dreams and transient sleep disturbance during the initial weeks—are typically mild and self-limiting. Organizational and Expert Perspectives Major MS organizations have addressed LDN with measured positions. The National Multiple Sclerosis Society (2024) recognizes the popularity of off-label LDN use but notes that most supporting evidence remains anecdotal or derived from small trials. They advise patients to discuss LDN with their neurologists, particularly regarding potential interactions with opioid medications. The MS Trust (2020) acknowledges reported benefits among some individuals while emphasizing that LDN is unlicensed for MS in the UK and lacks robust clinical evidence. Their guidance appropriately cautions that LDN should not replace proven disease-modifying therapies. The LDN Research Trust (2020) provides a more optimistic assessment, summarizing practitioner reports indicating potential benefits for fatigue, pain, and spasticity. They position LDN as a complementary approach that may contribute to disease stabilization through immune modulation and endorphin enhancement, while acknowledging the need for larger confirmatory trials. Compounding Pharmacy Considerations Since LDN is unavailable in commercial formulations at therapeutic doses, it requires preparation by compounding pharmacies. This specialized process involves creating precisely customized doses—typically 1.5 mg to 4.5 mg—tailored to individual patient needs. The quality of compounded LDN matters significantly. Reputable compounding pharmacies adhere to standards established by the United States Pharmacopeia (USP) and state boards of pharmacy, ensuring medications are prepared in controlled environments using pharmaceutical-grade ingredients. Patients and healthcare providers should consider pharmacies with accreditation from organizations such as the Pharmacy Compounding Accreditation Board (PCAB). When selecting a compounding pharmacy, it's reasonable to inquire about batch testing procedures, ingredient sourcing, and established protocols. Consistent compounding practices help maintain stable therapeutic levels and minimize variability between refills—an important consideration for ongoing therapy. Clinical Considerations and Patient Selection For clinicians considering LDN, several practical points merit attention. Patient selection should account for current opioid use, as LDN is contraindicated in patients taking opioid medications due to potential precipitation of withdrawal. A washout period of 7 to 14 days is typically recommended before initiating LDN in patients transitioning off opioids. Dosing typically begins at 1.5 mg nightly, with gradual titration to the target dose of 4.5 mg over 2 to 4 weeks. This approach minimizes initial side effects and allows for individual optimization. Some patients find their best response at doses below 4.5 mg, highlighting the importance of individualized titration—a hallmark of integrative medicine practice. LDN may also benefit symptoms beyond those traditionally studied, including brain fog and chronic pain conditions such as complex regional pain syndrome. Emerging evidence suggests potential metabolic benefits, including improved insulin sensitivity, which may be relevant for patients with concurrent metabolic concerns. "I want to highlight three real people who have beaten MS. First, Linda—founder of one of the most prominent LDN support groups—who has lived this journey herself. Second, one of my own patients whose neurologist confirmed she is now in remission; she has stopped all her MS medications through our combined integrative approach with LDN. And third, Dr. Terry Wahls, who reversed her own MS with her modified paleo diet and functional medicine principles. These aren't theoretical possibilities—these are real outcomes from real people." Yoon Hang Kim MD Conclusion Low-dose naltrexone represents a promising adjunctive option within the integrative medicine toolkit for multiple sclerosis. Current evidence consistently demonstrates safety and tolerability, with some studies suggesting meaningful improvements in quality of life, mental health, and spasticity. While efficacy data remain mixed and larger randomized controlled trials are needed, LDN's favorable risk profile and low cost make it a reasonable consideration for patients seeking complementary approaches. Within a functional medicine framework, LDN's proposed mechanism of supporting endogenous opioid and immune regulatory systems aligns with the broader philosophy of working with the body's inherent healing capacity. For patients and practitioners navigating MS treatment, LDN offers an additional option that may enhance quality of life when integrated thoughtfully with established conventional therapies. As with all therapeutic decisions, open communication between patients and healthcare providers remains essential. Patients considering LDN should discuss it with their neurologist and integrative medicine practitioner to ensure appropriate coordination of care. Low-Dose Naltrexone in Multiple Sclerosis: An Integrative Medicine Perspective At Direct Integrative Care, Dr. Kim is dedicated to guiding you on your path to wellness through a deeply personalized and supportive approach. We focus on integrative medicine, looking beyond symptoms to uncover the root causes of chronic conditions and develop a treatment plan tailored specifically to your unique health journey. By combining compassionate care with innovative therapies, our goal is to empower you with the knowledge and tools needed to achieve lasting health. We invite you to explore our website to learn more about how our patient-centered practice can help you find balance and vitality.  Yoon Hang Kim MD Integrative & Functional Medicine Physician Virtual Practice Serving IA, IL, MO, FL, GA, and TX www.directintegrativecare.com Yoon Hang Kim MD MPH Expert in Integrative & Functional Medicine References Brown, N., & Panksepp, J. (2009). Low-dose naltrexone for disease prevention and quality of life. Medical Hypotheses, 72 (3), 333–337. https://doi.org/10.1016/j.mehy.2008.06.048 Cree, B. A. C., Kornyeyeva, E., & Goodin, D. S. (2010). Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Annals of Neurology, 68 (2), 145–150. https://doi.org/10.1002/ana.22006 Gironi, M., Martinelli, V., Brambilla, E., Furlan, R., Panerai, A. E., Comi, G., & Sacerdote, P. (2008). A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis. Multiple Sclerosis, 14 (8), 1076–1083. https://doi.org/10.1177/1352458508095828 LDN Research Trust. (2020). Low dose naltrexone for MS . https://ldnresearchtrust.org/low-dose-naltrexone-ms Ludwig, M. D., Turel, A. P., Eller, M. E., & Smith, T. (2016). Long-term treatment with low dose naltrexone maintains stable health in patients with multiple sclerosis. Multiple Sclerosis Journal – Experimental, Translational and Clinical, 2 (3), 1–9. https://doi.org/10.1177/2055217316672242 MS Trust. (2020). Low dose naltrexone (LDN) . https://mstrust.org.uk/a-z/low-dose-naltrexone-ldn National Multiple Sclerosis Society. (2024). Low-dose naltrexone usage in multiple sclerosis . https://www.nationalmssociety.org/news-and-magazine/momentum-magazine/living-well/low-dose-naltrexone-usage-in-ms Raknes, G., Småbrekke, L., & Nilsen, K. B. (2017). Low dose naltrexone in multiple sclerosis: Effects on medication use. PLOS ONE, 12 (11), Article e0187423. https://doi.org/10.1371/journal.pone.0187423 Sharafaddinzadeh, N., Moghtaderi, A., Kashipazha, D., Majdinasab, N., & Shalbafan, M. R. (2010). The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: A randomized placebo-controlled trial. Multiple Sclerosis, 16 (8), 964–969. https://doi.org/10.1177/1352458510366854 Walton, C., King, R., Rechtman, L., Kaye, W., Leray, E., Marrie, R. A., ... & Baneke, P. (2020). Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Multiple Sclerosis Journal, 26 (14), 1816–1821. https://doi.org/10.1177/1352458520970841 Younger, J., & Mackey, S. (2014). Low-dose naltrexone for chronic pain: A systematic review of the clinical evidence. Clinical Rheumatology, 33 (4), 451–459. https://doi.org/10.1007/s10067-014-2517-2 Zagon, I. S., & McLaughlin, P. J. (2017). Endogenous opioids in the etiology and treatment of multiple sclerosis. In Multiple sclerosis: Perspectives in treatment and pathogenesis  (pp. 125–142). Codon Publications. https://doi.org/10.15586/codon.multiplesclerosis.2017.ch8

Role of Probiotics in Integrative Medicine and Functional Medicine: Evidence-Based Role of Probiotics in Integrative and Functional Medicine: A Clinical Review Yoon Hang Kim, MD, MPH About Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified integrative medicine physician with over 20 years of clinical experience. He completed his integrative medicine fellowship at the University of Arizona under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture, and integrative/holistic medicine. Through his telemedicine practice, Dr. Kim specializes in utilizing LDN or Low Dose Naltrexone for treating autoimmune conditions, chronic pain, integrative oncology, and complex conditions including fibromyalgia, chronic fatigue, MCAS, and mold toxicity. He is the author of three books and more than 20 articles, and has helped establish integrative medicine programs at institutions nationwide. Professional:   www.yoonhangkim.com  | Clinical:   www.directintegrativecare.com Abstract Probiotics have become a cornerstone of integrative medicine and functional medicine practice, offering evidence-based options for gastrointestinal conditions and broader health optimization. This clinical review synthesizes current evidence from randomized controlled trials, systematic reviews, and meta-analyses examining probiotic efficacy for antibiotic-associated diarrhea, irritable bowel syndrome, ulcerative colitis, and pouchitis. The integrative medicine approach emphasizes strain-specific and disease-specific selection, individualized patient assessment, and integration within comprehensive treatment protocols. Clinical evidence supports targeted probiotic interventions when appropriately matched to patient presentations, with demonstrated efficacy for specific strains including Lactobacillus rhamnosus  GG, Saccharomyces boulardii , and high-concentration multi-strain preparations containing the De Simone Formulation. Introduction The integration of probiotic therapy into clinical practice represents one of the most significant advances in integrative medicine over the past two decades. Defined as live microorganisms that confer health benefits when administered in adequate amounts, probiotics have evolved from complementary therapy to evidence-based intervention for multiple gastrointestinal conditions. Within the functional medicine framework, probiotics serve as foundational tools for addressing the underlying dysbiosis that contributes to chronic disease—and they're increasingly central to how we manage complex, ongoing conditions. Those of us practicing integrative medicine have long recognized the therapeutic potential of targeted microbiome modulation. Where conventional medicine often addresses symptoms in isolation, integrative medicine combines standard care with complementary approaches to create treatment strategies that recognize gut health as central to overall wellness. This aligns with the functional medicine principle of treating root causes rather than simply managing downstream effects. The clinical evidence supporting probiotic efficacy has matured substantially, with high-quality systematic reviews and meta-analyses now guiding our recommendations. However, a critical principle has emerged: probiotic effects are fundamentally strain-specific and disease-specific. Benefits demonstrated with one strain or formulation cannot be extrapolated to others, even within the same species. This specificity demands that clinicians maintain detailed knowledge of which preparations are supported for which indications. Prevention of Antibiotic-Associated Diarrhea Antibiotic-associated diarrhea represents one of the strongest evidence-based applications for probiotic therapy in integrative medicine practice. Antibiotics disrupt commensal gut flora, creating conditions that favor pathogenic overgrowth and osmotic imbalance. This results in diarrhea in 5-39% of patients depending on the antibiotic class and patient population. From a functional medicine perspective, this iatrogenic dysbiosis is a preventable consequence of necessary antimicrobial therapy—and probiotics can help treat or prevent these complications by restoring microbial balance during and after antibiotic use. Multiple high-quality meta-analyses demonstrate that co-administration of probiotics with antibiotics reduces AAD incidence by approximately 37-51%, with effects most pronounced when probiotic therapy starts early in the antibiotic course. The landmark systematic review by Hempel and colleagues published in JAMA analyzed 82 randomized controlled trials and established level A evidence for probiotic prophylaxis against AAD. Two strains have demonstrated particularly robust efficacy: Lactobacillus rhamnosus  GG and Saccharomyces boulardii . These organisms show consistent benefit across pediatric and adult populations aged 18-64 years. The American Academy of Family Physicians now recommends probiotic co-administration for AAD prevention—a reflection of how this evidence has been integrated into mainstream practice guidelines. It's worth noting that evidence for AAD prevention is less robust in elderly populations over 65 years. The PLACIDE trial, a large multicenter randomized controlled trial published in The Lancet, found no significant benefit from a multi-strain Lactobacillus  and Bifidobacterium  preparation in older hospitalized patients receiving antibiotics. This finding underscores the importance of patient selection and the limitations of extrapolating efficacy across populations—a principle central to both integrative medicine and functional medicine practice. Probiotic Therapy in Irritable Bowel Syndrome Irritable bowel syndrome exemplifies the complex, multifactorial conditions where integrative medicine and functional medicine approaches offer distinct advantages over conventional symptomatic management. The functional medicine model conceptualizes IBS as a manifestation of underlying gut-brain axis dysfunction, intestinal permeability alterations, and microbiome imbalance—not simply a diagnosis of exclusion to be managed with antispasmodics. Systematic reviews demonstrate that probiotics provide modest but clinically meaningful improvement in global IBS symptoms, including abdominal pain, bloating, and flatulence. Meta-analyses suggest approximately 21% reduction in persistent symptoms compared with placebo, though effects vary considerably by strain, preparation, and IBS subtype. Multi-strain preparations generally outperform single-strain products, reflecting the complexity of the microbiome ecosystem we're trying to restore. Evidence for specific strains remains mixed, illustrating the challenges of translating research findings into clinical practice. Lactobacillus plantarum  299v has been evaluated in multiple randomized trials with conflicting results. The trial by Ducrotté and colleagues demonstrated significant symptom improvement, while other studies found no benefit over placebo. This variability highlights the need for individualized treatment selection—something we emphasize in both integrative medicine and functional medicine. From my perspective, probiotic therapy for IBS shouldn't be considered in isolation. It's one component of a comprehensive protocol addressing dietary triggers, stress management, motility support, and intestinal barrier function. The functional medicine approach emphasizes identifying and treating the unique constellation of factors contributing to each patient's presentation rather than applying standardized protocols uniformly. When we address these factors together, we see meaningful improvements in quality of life and long-term health. Adjunctive Therapy in Ulcerative Colitis and Pouchitis The application of probiotics in inflammatory bowel disease represents a sophisticated integration of microbiome science with conventional gastroenterological care—precisely the synthesis that defines modern integrative medicine. While probiotic therapy cannot replace standard pharmacological management of ulcerative colitis, high-quality evidence supports its role as effective adjunctive treatment in appropriate patients. High-concentration multi-strain probiotics containing the De Simone Formulation (currently available as Visbiome and historically formulated in VSL#3 prior to 2016) have demonstrated efficacy in inducing and maintaining remission in mild-to-moderate ulcerative colitis when combined with standard therapies. The specificity of this evidence is critical: these results apply to this particular formulation and cannot be extrapolated to other probiotic products regardless of marketing claims or apparent similarity in strain composition. Other probiotics may not provide the same benefits. Randomized controlled trials by Bibiloni et al. (2005), Sood et al. (2009), and Tursi et al. (2010) report remission rates approaching 77% in patients with active mild-to-moderate disease receiving the De Simone Formulation as adjunctive therapy. These findings have been incorporated into clinical practice guidelines, representing successful translation of integrative medicine research into mainstream gastroenterology recommendations. Pouchitis following ileal pouch-anal anastomosis represents perhaps the strongest indication for probiotic therapy in gastroenterology. The seminal work by Gionchetti and colleagues established that high-concentration multi-strain probiotics effectively prevent pouchitis recurrence and maintain remission in this challenging patient population. For functional medicine practitioners managing post-surgical patients, this is an essential evidence-based intervention. The Principle of Strain and Disease Specificity A foundational principle for anyone prescribing probiotics is that efficacy is both strain-specific and disease-specific. The systematic review and meta-analysis by McFarland and colleagues published in Frontiers in Medicine provides compelling evidence that benefits cannot be generalized across strains, even within the same species. A Lactobacillus  strain effective for AAD prevention may offer no benefit for IBS or inflammatory bowel disease. This has profound implications for clinical practice. The functional medicine approach demands precise matching of probiotic strains to clinical indications, avoiding the common but inappropriate practice of recommending generic "probiotic supplements" without attention to formulation specifics. We need to verify that recommended products contain the specific strains supported by clinical trial evidence for the intended indication. Emerging research suggests potential probiotic applications beyond gastrointestinal health, including cognitive function and mental health outcomes. Umbrella reviews of meta-analyses by Xie et al. (2021) indicate moderate-quality evidence for cognitive benefits, though further randomized controlled trials are needed before we can make definitive recommendations. This expanding evidence base reflects what integrative medicine has long recognized: gut health influences systemic function through multiple pathways, including the gut-brain axis. Probiotics and Immune Function In functional medicine and integrative medicine practice, we recognize that immune function doesn't exist in isolation—it's deeply connected to gut health. The gastrointestinal tract houses roughly 70% of the body's immune tissue, making the relationship between beneficial bacteria and immune response more than theoretical. Clinical research has shown that specific probiotic strains can modulate immune function in meaningful ways. Strains including Lactobacillus acidophilus , Bifidobacterium breve , and Bifidobacterium longum  have demonstrated effects on immune markers and may help reduce susceptibility to certain infections. These beneficial bacteria work by competing with pathogens for resources and attachment sites, producing antimicrobial compounds, and signaling to immune cells in the gut mucosa. The National Center for Complementary and Integrative Health acknowledges probiotics as a legitimate area of research for immune support, though they appropriately note that evidence varies by strain and condition. This is consistent with what we see in clinical practice: some patients with chronic conditions—fibromyalgia, chronic fatigue, autoimmune disorders—respond well to targeted probiotic protocols as part of comprehensive treatment, while others see minimal benefit. The key is individualized assessment. From a practical standpoint, I recommend that patients work with their healthcare team to select probiotic products based on clinical evidence rather than marketing. Not all probiotic supplements are created equal—quality and potency vary significantly between products, and the strains that work for one condition may not work for another. A thorough evaluation that considers the whole patient—including stress, diet, sleep, and existing conditions—remains essential for developing effective treatment plans. Safety Considerations Probiotics demonstrate excellent safety profiles in healthy individuals, with adverse events typically limited to minor gastrointestinal symptoms including transient bloating, gas, or altered bowel habits during initial therapy. These effects generally resolve with continued use as the microbiome adjusts. However, certain populations require heightened caution. Serious adverse events, while rare, have been reported in immunocompromised patients, those with central venous catheters, critically ill patients, and individuals with severe acute pancreatitis. The functional medicine emphasis on comprehensive patient assessment becomes essential when determining probiotic candidacy in complex or medically fragile patients. Clinical judgment should prioritize strains with documented safety profiles for the specific patient population. The NIH Office of Dietary Supplements maintains updated safety information that clinicians should consult when managing higher-risk patients. As with any intervention, patients should discuss probiotic use with their healthcare provider, particularly if they have underlying health conditions or are taking other medications. Conclusion Probiotic therapy represents a mature, evidence-based intervention within the integrative medicine and functional medicine toolkit. The strongest evidence supports specific applications: AAD prevention with L. rhamnosus  GG or S. boulardii , adjunctive ulcerative colitis management with high-concentration De Simone Formulation products, and pouchitis prevention following surgery. The functional medicine principle of individualized treatment selection applies directly to probiotic prescribing. Clinicians must match specific strains to specific indications based on clinical trial evidence rather than relying on generic recommendations or marketing claims. The integrative medicine approach positions probiotic therapy within comprehensive treatment protocols addressing diet, lifestyle, stress, and other factors contributing to gastrointestinal dysfunction. As research continues to elucidate microbiome-health relationships, applications for probiotic therapy will likely expand. Practitioners should maintain current knowledge of evolving evidence while adhering to the fundamental principle that probiotic benefits are strain-specific and disease-specific—a principle that protects patients from ineffective interventions and ensures optimal outcomes. At Direct Integrative Care, Dr. Kim is dedicated to guiding you on your path to wellness through a deeply personalized and supportive approach. We focus on integrative medicine, looking beyond symptoms to uncover the root causes of chronic conditions and develop a treatment plan tailored specifically to your unique health journey. By combining compassionate care with innovative therapies, our goal is to empower you with the knowledge and tools needed to achieve lasting health. We invite you to explore our website to learn more about how our patient-centered practice can help you find balance and vitality.  Yoon Hang Kim MD Integrative & Functional Medicine Physician Virtual Practice Serving IA, IL, MO, FL, GA, and TX www.directintegrativecare.com References Allen SJ, Wareham K, Wang D, et al. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): A randomised, double-blind, placebo-controlled, multicentre trial. Lancet . 2013;382(9900):1249-1257. Bibiloni R, Fedorak RN, Tannock GW, et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol . 2005;100(7):1539-1546. Ducrotté P, Sawant P, Jayanthi V. Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World J Gastroenterol . 2012;18(30):4012-4018. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double-blind, placebo-controlled trial. Gastroenterology . 2000;119(2):305-309. Hempel S, Newberry SJ, Maher AR, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: A systematic review and meta-analysis. JAMA . 2012;307(18):1959-1969. McFarland LV, Ship N, Auclair J, Millette M. Strain-specificity and disease-specificity of probiotic efficacy: A systematic review and meta-analysis. Front Med . 2018;5:124. National Institutes of Health, Office of Dietary Supplements. Probiotics: Health professional fact sheet. Updated 2025. https://ods.od.nih.gov/factsheets/Probiotics-HealthProfessional/ Sood A, Midha V, Makharia GK, et al. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol . 2009;7(11):1202-1209. Tursi A, Brandimarte G, Papa A, et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: A double-blind, randomized, placebo-controlled study. Am J Gastroenterol . 2010;105(10):2218-2227. Xie C, Li X, Zhu J, Sun J, Wang X. Probiotics and cognitive-related health outcomes: An umbrella review of meta-analyses of randomized controlled trials. Nutr Rev . 2021;79(11):1259-1269.

Understanding Menopause Supplements: An Evidence-Based Guide to Benefits, Limitations, and Informed Decision-Making Understanding Menopause Supplements: About Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified integrative medicine physician with over 20 years of clinical experience. He completed his integrative medicine fellowship at the University of Arizona under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture, and integrative/holistic medicine. Through his telemedicine practice, Dr. Kim specializes in utilizing LDN or Low Dose Naltrexone for treating autoimmune conditions, chronic pain, integrative oncology, and complex conditions including fibromyalgia, chronic fatigue, MCAS, and mold toxicity. He is the author of three books and more than 20 articles, and has helped establish integrative medicine programs at institutions nationwide. Professional:   www.yoonhangkim.com  | Clinical:   www.directintegrativecare.com Introduction Menopause represents a universal biological transition, marking the permanent end of menstrual periods and natural fertility. Confirmed retrospectively after 12 consecutive months without menstruation, menopause typically occurs between ages 45 and 55, though individual variation is substantial (National Institute on Aging, 2024; World Health Organization, 2024). This life stage, while entirely normal, often brings challenging symptoms that significantly impact quality of life, driving many individuals to seek relief through various therapeutic approaches. While hormone therapy (HT) remains the most effective treatment for menopausal symptoms, concerns about potential risks—particularly following the Women's Health Initiative findings—have prompted substantial interest in complementary and alternative approaches. Dietary supplements have emerged as popular options, with research suggesting that certain plant-based compounds may offer modest symptom relief for some individuals. However, it is essential to approach these products with realistic expectations: benefits tend to be ingredient-specific and generally smaller than those achieved with conventional hormone therapy (Franco et al., 2016; Pokushalov et al., 2025). This comprehensive review examines the current scientific evidence surrounding menopause supplements, providing healthcare consumers and practitioners with the information necessary to make informed decisions about integrating these products into a broader wellness strategy. The Biology of Menopause: Understanding What Changes Menopause occurs when the ovaries cease releasing eggs and estrogen production declines substantially, resulting in the permanent cessation of menstrual periods and the end of natural reproductive capacity (National Institute on Aging, 2024; World Health Organization, 2024). Natural menopause is diagnosed clinically after 12 consecutive months of amenorrhea without another identifiable medical cause or hormonal intervention. The menopausal transition, commonly termed perimenopause, may span several years and is characterized by fluctuating and eventually declining levels of estrogen and progesterone. These hormonal shifts drive the constellation of symptoms many individuals experience, including vasomotor symptoms (hot flashes and night sweats), sleep disturbances, mood changes, cognitive concerns, and genitourinary changes such as vaginal dryness (National Institute on Aging, 2024; World Health Organization, 2024). The severity, duration, and specific manifestation of these symptoms vary considerably among individuals, influenced by genetic, lifestyle, and environmental factors. Beyond immediate symptom burden, the decline in estrogen has long-term health implications. Accelerated bone loss following menopause increases osteoporosis and fracture risk, while the cardiovascular advantage women typically enjoy over men gradually diminishes as estrogen levels fall (World Health Organization, 2024). These considerations underscore the importance of a comprehensive approach to perimenopausal and postmenopausal health that addresses both symptomatic relief and long-term disease prevention. Evaluating the Evidence: Do Menopause Supplements Work? The scientific literature on menopause supplements presents a complex picture, with evidence varying substantially by ingredient, formulation, dose, and study quality. Meta-analyses and systematic reviews provide the most reliable synthesis of available data, though even these analyses reveal considerable heterogeneity in findings. Phytoestrogens and Plant-Based Therapies A landmark 2016 systematic review and meta-analysis published in JAMA examined 62 studies encompassing 6,653 women and found that phytoestrogen supplementation was associated with modest reductions in hot flash frequency and vaginal dryness scores compared to placebo. However, the same analysis found no significant reduction in night sweats, and the authors noted substantial heterogeneity in study quality, with 74% of included trials demonstrating high risk of bias in three or more areas (Franco et al., 2016). Similarly, a Cochrane systematic review examining phytoestrogens for menopausal vasomotor symptoms concluded that no conclusive evidence supports the effectiveness of phytoestrogen supplements in reducing hot flash frequency or severity in perimenopausal or postmenopausal women. The review noted a strong placebo effect across most trials, with placebo groups experiencing symptom reductions ranging from 1% to 59% (Lethaby et al., 2013). These findings highlight both the potential for modest benefit and the importance of tempering expectations. Combination Botanical Formulations More recent research has examined combination approaches. A 2025 randomized, double-blind, placebo-controlled trial evaluated the effects of a supplement combining black cohosh, soy isoflavones, and SDG lignans in 96 postmenopausal women over 90 days. The treatment group demonstrated statistically significant improvements across all Menopause Rating Scale domains: somatic symptoms (54.3% difference), psychological symptoms (54.3% difference), urogenital symptoms (37.3% difference), and total score (48.0% difference). The safety profile was favorable, with few adverse events reported (Pokushalov et al., 2025). While these results are encouraging, they represent a single trial with a relatively small sample size and short duration. Replication in larger, longer-term studies across diverse populations will be necessary before definitive conclusions can be drawn. Nevertheless, such findings suggest that thoughtfully formulated combination products may offer greater benefit than single-ingredient supplements. Key Ingredients: What the Science Supports Vasomotor Symptom Support Among the most studied botanicals for menopausal vasomotor symptoms are black cohosh (Actaea racemosa), soy isoflavones, and SDG lignans (secoisolariciresinol diglucoside, derived primarily from flaxseed). These compounds have demonstrated varying degrees of efficacy in clinical trials, though results remain inconsistent across studies (Franco et al., 2016; Pokushalov et al., 2025). Other plant-based options sometimes incorporated into menopause formulas include red clover, sage, and dong quai, though evidence supporting these ingredients is generally weaker or more inconsistent, positioning them as secondary or adjunctive options (Franco et al., 2016; Lethaby et al., 2013). Mood, Sleep, and Stress Support Ingredients such as magnesium, L-theanine, and certain adaptogens (notably ashwagandha) are frequently incorporated into menopause supplements targeting sleep quality and stress management. While these compounds have demonstrated effects in broader anxiety and sleep research, menopause-specific data remain limited. Individuals experiencing significant mood or sleep disturbances should discuss these symptoms with a healthcare provider, as they may warrant targeted evaluation and treatment. Bone and Cardiometabolic Health Foundational nutrients for bone health in midlife and beyond include vitamin D, calcium, and increasingly, vitamin K2. These become particularly important as estrogen decline accelerates bone resorption (National Institute on Aging, 2024; World Health Organization, 2024). Omega-3 fatty acids may support cardiovascular and inflammatory health, which gains relevance as cardiometabolic risk increases following menopause (World Health Organization, 2024). These nutrients, while not directly targeting acute menopausal symptoms, address important long-term health considerations that should be part of comprehensive perimenopausal care. Choosing Wisely: A Framework for Supplement Selection Match Formulation to Primary Concerns For hot flashes and night sweats, look for products containing clinically studied doses of standardized soy isoflavones, black cohosh, or combination formulas similar to those evaluated in controlled trials. Avoid products that obscure ingredient amounts within proprietary blends, as dose matters substantially for efficacy (Pokushalov et al., 2025). For sleep, mood, and stress concerns, select formulations that specify evidence-based doses and provide clear information about potential interactions with prescription medications, particularly antidepressants or anxiolytics. Prioritize Quality and Transparency Third-party verification marks (such as USP or NSF certification) provide some assurance that labeled ingredients and doses match actual product contents and that contamination risks are minimized. Avoid products making disease-treatment claims, incorporating stimulant blends, or combining numerous herbs at low, unstudied doses. Remember that dietary supplements are not FDA-approved to treat menopause and may interact with medications or affect individuals with liver disease (World Health Organization, 2024). Seek Professional Guidance Prefer products and ingredients supported by randomized controlled trials or systematic reviews specifically conducted in peri- or postmenopausal populations, rather than relying solely on anecdotal testimonials (Franco et al., 2016; Pokushalov et al., 2025). Most importantly, discuss any new supplement with a clinician familiar with menopause care—whether a gynecologist, menopause specialist, or integrative/functional medicine practitioner—particularly if there is a history of hormone-sensitive cancers, clotting disorders, liver disease, or polypharmacy (National Institute on Aging, 2024; World Health Organization, 2024). When Supplements May Be Appropriate Individuals may reasonably consider supplement use when menopausal symptoms affect daily life but they cannot, do not wish to, or are not yet candidates for systemic hormone therapy—for example, during early symptom evaluation, with mild symptom burden, or when certain risk profiles make HT less suitable (National Institute on Aging, 2024; World Health Organization, 2024). Supplements may also serve as adjuncts to lifestyle modifications including dietary optimization, regular physical activity, and stress management strategies (World Health Organization, 2024). Importantly, supplements work best as components of a broader, individualized care plan developed collaboratively with healthcare providers who can monitor safety, assess for drug-supplement interactions, and evaluate treatment response over time. They are not substitutes for comprehensive medical evaluation or, when indicated, evidence-based pharmacological therapy. Conclusion Menopause supplements occupy a nuanced space in symptom management—neither entirely ineffective nor comparable to hormone therapy in efficacy. Current evidence suggests modest benefits for certain ingredients and combinations, particularly for vasomotor symptoms, though results remain inconsistent and effect sizes generally smaller than those achieved with conventional treatment. For individuals seeking complementary approaches, evidence-based ingredient selection, attention to product quality, and professional oversight represent the foundations of safe and rational supplement use. As research continues to evolve—with newer trials examining combination formulas and longer-term outcomes—our understanding of these products will undoubtedly deepen. In the interim, informed consumers and practitioners can navigate this landscape by maintaining realistic expectations, prioritizing high-quality evidence, and integrating supplements thoughtfully within comprehensive perimenopausal and postmenopausal care strategies. At Direct Integrative Care, Dr. Kim is dedicated to guiding you on your path to wellness through a deeply personalized and supportive approach. We focus on integrative medicine, looking beyond symptoms to uncover the root causes of chronic conditions and develop a treatment plan tailored specifically to your unique health journey. By combining compassionate care with innovative therapies, our goal is to empower you with the knowledge and tools needed to achieve lasting health. We invite you to explore our website to learn more about how our patient-centered practice can help you find balance and vitality.  Yoon Hang Kim MD Integrative & Functional Medicine Physician Virtual Practice Serving IA, IL, MO, FL, GA, and TX www.directintegrativecare.com Yoon Hang Kim MD Integrative & Functional Medicine Physician References Franco, O. H., Chowdhury, R., Troup, J., Voortman, T., Kunutsor, S., Kavousi, M., Oliver-Williams, C., & Muka, T. (2016). Use of plant-based therapies and menopausal symptoms: A systematic review and meta-analysis. JAMA, 315 (23), 2554–2563. https://doi.org/10.1001/jama.2016.8012 Lethaby, A., Marjoribanks, J., Kronenberg, F., Roberts, H., Eden, J., & Brown, J. (2013). Phytoestrogens for menopausal vasomotor symptoms. Cochrane Database of Systematic Reviews, (12), Article CD001395. https://doi.org/10.1002/14651858.CD001395.pub4 National Institute on Aging. (2024, October 16). What is menopause? U.S. Department of Health and Human Services. https://www.nia.nih.gov/health/menopause/what-menopause Pokushalov, E., Ponomarenko, A., Garcia, C., Kasimova, L., Pak, I., Shrainer, E., Romanova, A., Kudlay, D., Johnson, M., & Miller, R. (2025). Assessing the combined effects of black cohosh, soy isoflavones, and SDG lignans on menopausal symptoms: A randomized, double-blind, placebo-controlled clinical trial. European Journal of Nutrition, 64 (3), 138. https://doi.org/10.1007/s00394-025-03588-y World Health Organization. (2024, October 16). Menopause [Fact sheet]. https://www.who.int/news-room/fact-sheets/detail/menopause

By Yoon Hang "John" Kim, MD, MPH About Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified integrative medicine physician with over 20 years of clinical experience. He completed his integrative medicine fellowship at the University of Arizona under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture, and integrative/holistic medicine. Through his telemedicine practice, Dr. Kim specializes in utilizing LDN or Low Dose Naltrexone for treating autoimmune conditions, chronic pain, integrative oncology, and complex conditions including fibromyalgia, chronic fatigue, MCAS, and mold toxicity. He is the author of three books and more than 20 articles, and has helped establish integrative medicine programs at institutions nationwide. Professional:   www.yoonhangkim.com  | Clinical:   www.directintegrativecare.com Niacinamide, also known as nicotinamide, represents one of the most versatile and well-tolerated supplements in integrative medicine. As the amide form of vitamin B3, this water-soluble nutrient serves as a precursor to nicotinamide adenine dinucleotide (NAD⁺) and its phosphorylated derivative (NADP⁺)—essential coenzymes involved in over 500 redox reactions critical for energy metabolism, DNA repair, and cellular resilience. Unlike its sibling molecule nicotinic acid (niacin), niacinamide does not induce the characteristic cutaneous flushing that many patients find intolerable, rendering it a preferable option for therapeutic use across multiple clinical applications. Understanding the Biochemistry: Why Niacinamide Matters The clinical significance of niacinamide stems from its foundational role in cellular energy production. NAD⁺ levels decline with age, chronic stress, and disease states, creating a cellular energy deficit that manifests across multiple organ systems. Niacinamide efficiently replenishes NAD⁺ pools via the salvage pathway, maintaining cellular energy production through glycolysis, fatty acid oxidation, and the tricarboxylic acid cycle. Beyond energy metabolism, NAD⁺ activates poly(ADP-ribose) polymerase (PARP) enzymes essential for DNA repair and sirtuins involved in gene regulation and longevity pathways. This dual mechanism—supporting both cellular energy and genomic stability—positions niacinamide as a foundational intervention in protocols addressing metabolic dysregulation, chronic inflammation, and age-related cellular decline. The distinction from niacin bears clinical importance. While both compounds share identical vitamin functions, their pharmacological profiles diverge significantly. Niacin has high affinity for the G-protein-coupled receptor HM74A, triggering prostaglandin release and the vasodilation responsible for the uncomfortable flushing reaction. Niacinamide lacks this receptor affinity, making it extremely well-tolerated topically and orally—clinical tests demonstrate no stinging at concentrations up to 10% and no irritation up to 5% in dermatological applications. Antioxidant and Anti-Inflammatory Mechanisms In functional medicine practice, niacinamide's value extends beyond NAD⁺ repletion to encompass robust antioxidant and anti-inflammatory effects. Oxidative stress—the generation of reactive oxygen species (ROS) exceeding cellular antioxidant capacity—represents a core driving factor in chronic disease and aging. Niacinamide attenuates oxidative burden through multiple mechanisms. By maintaining favorable NAD⁺/NADPH ratios, niacinamide decreases NADPH oxidase expression and activity, reducing superoxide radical concentrations. It increases superoxide dismutase levels and enhances catalase activity, transforming hydrogen peroxide back into oxygen and water. Additionally, niacinamide demonstrates direct scavenger activity, particularly against hydroxyl radicals. The anti-inflammatory properties operate through PARP-1 regulation, COX-2 inhibition, and modulation of NF-κB-mediated transcription. Clinical studies demonstrate reduced expression of pro-inflammatory cytokines including TNF-α, IL-1, IL-6, and IL-8, alongside increased production of anti-inflammatory mediators such as IL-10. This cytokine modulation is dose-dependent and has been validated in human clinical trials showing decreased IL-1αRA/IL-1α inflammatory skin biomarkers after topical application of 5% niacinamide formulations. Dermatological Applications: Beyond Cosmetic Benefits Topical and oral niacinamide has accumulated robust evidence in dermatology, representing perhaps the best-documented clinical application of this nutrient. Skin Barrier Enhancement and Photoaging Niacinamide strengthens the epidermal barrier by boosting ceramide synthesis through activation of serine palmitoyl transferase and accelerating keratinocyte differentiation. Clinical studies in Caucasian populations demonstrate significant reductions in yellowing, wrinkling, red blotchiness, and hyperpigmented spots associated with aging facial skin. The anti-yellowing effect stems from niacinamide's ability to reduce advanced glycation end products (AGEs) that accumulate in the cutaneous extracellular matrix. The skin lightening activity operates not through tyrosinase inhibition or reduced melanin synthesis, but rather by blocking melanosome transfer from melanocytes to surrounding keratinocytes. This mechanism makes niacinamide effective for hyperpigmentation disorders including melasma, axillary hyperpigmentation, lentigo senilis, and post-inflammatory hyperpigmentation. Compared to hydroquinone, niacinamide takes longer to demonstrate clinical efficacy but causes fewer adverse effects, making it suitable for longer treatment protocols. Acne and Inflammatory Skin Conditions For acne vulgaris, niacinamide addresses multiple pathogenic factors simultaneously: it reduces sebum production through mechanisms possibly involving HCA2 receptor activation (via conversion to niacin), exerts antimicrobial activity against Cutibacterium acnes , and suppresses inflammation. Clinical trials demonstrate efficacy levels comparable to clindamycin in anti-inflammatory activity, with concentrations of 2-4% showing particular effectiveness in oily skin types. The antimicrobial activity extends beyond direct bactericidal effects to include stimulation of antimicrobial peptide (AMP) synthesis and enhanced neutrophil function. Niacinamide activates innate immune pathways and enhances the activity of cathelicidin LL-37 through membrane modulation effects. Skin Cancer Chemoprevention Perhaps the most compelling dermatological application involves oral niacinamide for nonmelanoma skin cancer prevention. A landmark Phase III randomized trial published in the New England Journal of Medicine  demonstrated that 500 mg twice daily significantly reduced the rate of new nonmelanoma skin cancers (basal cell and squamous cell carcinomas) and actinic keratoses in high-risk individuals with sun-damaged skin. The chemopreventive mechanism operates through enhanced DNA repair of UV radiation-induced damage in keratinocytes and melanocytes. Niacinamide prevents post-UV exposure declines in cellular energy and repletes ATP to irradiated cells, facilitating nucleotide excision repair. Additionally, niacinamide reduces UV-induced immunosuppression and decreases inflammatory macrophages that may contribute to carcinogenesis. Memorial Sloan Kettering Cancer Center notes that while these protective effects against UV exposure are significant, niacinamide does not replace sunscreen and does not protect against sunburn. The cancer-preventive benefits appear specific to high-risk populations with documented sun damage. Musculoskeletal Applications: Osteoarthritis A double-blind, placebo-controlled pilot study published in Inflammation Research  demonstrated promising results for niacinamide in osteoarthritis management. In 72 patients treated for 12 weeks, niacinamide improved global arthritis impact by 29% compared to a 10% worsening in placebo subjects. Joint mobility increased by 4.5 degrees over controls, erythrocyte sedimentation rate decreased by 22%, and patients reduced their NSAID use by 13%. The mechanism likely involves NAD⁺-dependent modulation of chondrocyte metabolism, nitric oxide pathway regulation, and anti-inflammatory effects on joint tissues. While this represents a single pilot study requiring replication, the results align with niacinamide's established anti-inflammatory profile and suggest potential as an adjunctive intervention in integrative osteoarthritis protocols. Metabolic and Renal Applications Phosphorus Management in Chronic Kidney Disease Niacinamide inhibits intestinal phosphate absorption via the NaPi-2b cotransporter, effectively lowering serum phosphorus in hemodialysis patients when used adjunctively with phosphate binders. Meta-analyses support its efficacy and tolerability in this population, with potential benefits for mineral bone disorder management. However, increased risk of thrombocytopenia has been noted in hemodialysis patients, warranting careful monitoring. Beta-Cell Protection in Type 1 Diabetes Early investigations explored niacinamide for beta-cell preservation in newly diagnosed type 1 diabetes, though large trials have shown modest or inconsistent results for insulin secretion preservation. This application remains investigational. Neurological Considerations Historical orthomolecular approaches explored high-dose niacinamide for psychiatric conditions including schizophrenia and anxiety, based on observations linking pellagra to neuropsychiatric symptoms. Contemporary research focuses more on neuroprotective effects in degenerative models. Recent clinical trials demonstrate improvements in inner retinal and visual function in patients treated for glaucoma, suggesting potential applications in neurodegenerative conditions where NAD⁺ depletion and mitochondrial dysfunction play pathogenic roles. Safety Profile and Clinical Considerations Niacinamide is generally well-tolerated at therapeutic doses up to 3 grams daily. The most common adverse effects are mild gastrointestinal symptoms including nausea. Headache, fatigue, and dizziness have been reported at higher doses, and liver toxicity is possible with very high intake. Important Cautions Drug Interactions:  Niacinamide may increase blood levels of carbamazepine, necessitating monitoring in patients on this anticonvulsant. Cardiovascular Considerations:  Recent research has identified associations between a terminal metabolite of excess niacin supplementation and increased major adverse cardiovascular events (MACE). While this applies more directly to niacin than niacinamide, patients with cardiovascular history should discuss supplementation with their cardiologist. Thrombocytopenia Risk:  Meta-analyses of hemodialysis patients suggest increased risk of low platelets with niacinamide use. Not Interchangeable with Niacin:  Despite metabolic conversion between these compounds, their supplemental effects and side effect profiles differ significantly. Unauthorized substitution of niacin for niacinamide has caused unexpected flushing reactions. Practical Dosing Considerations Dosing depends on the clinical indication: Dermatological applications (topical):  2-5% formulations are typical, with 4-5% most commonly used in anti-aging protocols Skin cancer chemoprevention:  500 mg twice daily (1000 mg total daily) Osteoarthritis:  The pilot study used divided doses totaling approximately 3 grams daily General antioxidant/anti-inflammatory support:  Lower doses of 500-1000 mg daily are reasonable starting points As with any supplement protocol, individualization based on patient history, concurrent medications, and treatment goals remains essential. Integrative Medicine Perspective From an integrative medicine standpoint, niacinamide exemplifies the principle of working with the body's intrinsic repair mechanisms rather than against them. By supporting NAD⁺-dependent cellular processes that naturally decline with age and disease, niacinamide addresses upstream metabolic factors rather than simply suppressing downstream symptoms. Its remarkably broad safety profile, low cost, and compatibility with conventional therapies make it a practical adjunct in protocols addressing chronic inflammation, cardiometabolic disorders, skin health, and age-related decline. The multiple mechanisms of action—antioxidant, anti-inflammatory, barrier-supportive, and DNA repair-enhancing—allow it to address the interconnected pathophysiology characteristic of chronic conditions. Conclusion Niacinamide represents a well-characterized, evidence-based intervention with applications spanning dermatology, rheumatology, nephrology, and potentially neurology and oncology. Its safety profile permits use in diverse patient populations, though specific cautions apply to those on certain medications or with cardiovascular or renal conditions. As with all integrative interventions, optimal outcomes depend on appropriate patient selection, realistic expectations, and integration with comprehensive care plans. The strongest evidence supports dermatological applications, particularly skin cancer chemoprevention in high-risk individuals, where Phase III trial data provides robust clinical guidance. About Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified integrative medicine physician with over 20 years of clinical experience. He completed his integrative medicine fellowship at the University of Arizona under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture, and integrative/holistic medicine. Through his telemedicine practice, Dr. Kim specializes in utilizing LDN or Low Dose Naltrexone for treating autoimmune conditions, chronic pain, integrative oncology, and complex conditions including fibromyalgia, chronic fatigue, MCAS, and mold toxicity. He is the author of three books and more than 20 articles, and has helped establish integrative medicine programs at institutions nationwide. Professional:   www.yoonhangkim.com  | Clinical:   www.directintegrativecare.com References Marques C, et al. Mechanistic Insights into the Multiple Functions of Niacinamide: Therapeutic Implications and Cosmeceutical Applications in Functional Skincare Products. Antioxidants (Basel) . 2024;13(4):425. Jonas WB, Rapoza CP, Blair WF. The effect of niacinamide on osteoarthritis: a pilot study. Inflamm Res . 1996;45(7):330-334. Chen AC, Martin AJ, Choy B, et al. A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. N Engl J Med . 2015;373(17):1618-1626. Boo YC. Mechanistic basis and clinical evidence for the applications of nicotinamide (niacinamide) to control skin aging and pigmentation. Antioxidants . 2021;10:1315. Bissett DL, Miyamoto K, Sun P, et al. Topical niacinamide reduces yellowing, wrinkling, red blotchiness, and hyperpigmented spots in aging facial skin. Int J Cosmet Sci . 2004;26:231-238. Thompson BC, Surjana D, Halliday GM, et al. Nicotinamide enhances repair of ultraviolet radiation-induced DNA damage in primary melanocytes. Exp Dermatol . 2014;23(7):509-511. Rolfe HM. A review of nicotinamide: treatment of skin diseases and potential side effects. J Cosmet Dermatol . 2014;13(4):324-328. Memorial Sloan Kettering Cancer Center. About Herbs: Nicotinamide. Updated February 2023. Ferrell M, Wang Z, Anderson JT, et al. A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk. Nat Med . 2024;30(2):424-434. Zhang Y, Ma T, Zhang P. Efficacy and safety of nicotinamide on phosphorus metabolism in hemodialysis patients: A systematic review and meta-analysis. Medicine (Baltimore) . 2018;97(41):e12731. Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any supplement regimen. Dr. Yoon Hang "John" Kim is a board-certified integrative medicine physician specializing in chronic conditions and preventive care. Learn more at Direct Integrative Care .

Edited by Yoon Hang Kim MD MPH About Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified integrative medicine physician with over 20 years of clinical experience. He completed his integrative medicine fellowship at the University of Arizona under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture, and integrative/holistic medicine. Through his telemedicine practice, Dr. Kim specializes in autoimmune conditions, chronic pain, integrative oncology, and complex conditions including fibromyalgia, chronic fatigue, MCAS, and mold toxicity. He is the author of three books and more than 20 articles, and has helped establish integrative medicine programs at institutions nationwide. Professional:   www.yoonhangkim.com  | Clinical:   www.directintegrativecare.com Evidence-Based Review: Supplements for Male Sexual Function - Integrative Medicine Functional Medicine Perspective by Yoon Hang Kim MD MPH Evidence-Based Review: Supplements for Male Sexual Function - Integrative Medicine Functional Medicine Perspective San Antonio TX Introduction Erectile dysfunction affects an estimated 150 million men globally, with projections suggesting approximately 322 million men will be affected by 2025. The prevalence increases significantly with age—from 2–9% in men aged 40–49 years to 50–100% in men over 70. Beyond ED, concerns like low libido and hormonal shifts are common and can significantly impact quality of life. While PDE-5 inhibitors like sildenafil remain first-line therapy, many patients seek natural alternatives due to side effects, cost, drug interactions, or personal preference. This review synthesizes current clinical evidence from systematic reviews, meta-analyses, and randomized controlled trials examining supplements for male sexual function. As with any integrative approach, realistic expectations and shared decision-making remain essential. In my practice, I focus on identifying root causes of dysfunction and creating personalized treatment plans—considering physical, metabolic, hormonal, and even emotional factors that influence sexual vitality. Panax Ginseng: The Strongest Evidence Base Korean red ginseng ( Panax ginseng ) has the most robust evidence among herbal supplements for erectile dysfunction. A 2025 systematic review and meta-analysis of 14 RCTs involving 1,227 men published in the Journal of Herbal Medicine  demonstrated significant improvements across multiple domains of sexual function. Key Findings The meta-analysis found significant effects on erectile function (SMD = 1.20, 95% CI: 0.64–1.76), orgasmic function (SMD = 1.09), sexual desire (SMD = 1.02), intercourse satisfaction (SMD = 1.48), and overall satisfaction (SMD = 0.93). Notably, ginseng also improved serum testosterone levels (SMD = 0.54, 95% CI: 0.04–1.05). The 2022 Cochrane systematic review concluded that ginseng may enhance men's self-reported capacity for sexual intercourse with little to no effect on adverse events. A double-blind, placebo-controlled trial with 143 patients found significant improvements across all five IIEF domains after 8 weeks of 2,000 mg/day tissue-cultured mountain ginseng extract. How It Works Ginsenosides are believed to enhance nitric oxide synthesis in the corpus cavernosum and improve penile blood flow. Additional mechanisms include antioxidant effects, modulation of the hypothalamic-pituitary-gonadal axis, and direct effects on vascular smooth muscle relaxation. Practical Recommendations Typical dosing ranges from 900–3,000 mg/day of standardized Korean red ginseng extract for 4–12 weeks. Side effects are generally mild, including headache and gastrointestinal discomfort. Evidence quality remains moderate—ginseng shouldn't be considered equivalent to PDE-5 inhibitors, but it's a reasonable option for men seeking natural support. L-Arginine: The Nitric Oxide Precursor L-arginine is the physiological substrate for nitric oxide synthase, making it a logical choice for ED given NO's central role in penile erection. A 2019 systematic review and meta-analysis of 10 RCTs involving 540 patients demonstrated that arginine supplementation significantly improved erectile dysfunction compared to placebo. Clinical Evidence The meta-analysis found that L-arginine at dosages of 1,500–5,000 mg/day significantly improved ED (OR 3.37, 95% CI: 1.29–8.77, p = 0.01). Significant improvements were observed in IIEF subdomain scores for erectile function, intercourse satisfaction, orgasmic function, and overall satisfaction—though sexual desire scores remained unchanged. A 2022 multicentre, double-blind RCT published in the Journal of Endocrinological Investigation  examined high-dose L-arginine (6 g/day) for 3 months in patients with vasculogenic ED. Results showed significant improvements in IIEF-6 scores (p < 0.0001) and cavernous arteries peak systolic flow velocity in patients with mild-moderate ED. Notably, 74% of patients improved their ED severity category. The Pycnogenol Combination A 2023 meta-analysis in Frontiers in Endocrinology  examined the combination of L-arginine with Pycnogenol (French maritime pine bark extract). The combination produced significant improvements across all IIEF domains—erectile function (MD 8.9), intercourse satisfaction (MD 4.96), orgasmic function, overall satisfaction, and sexual desire. The synergy likely stems from Pycnogenol's ability to enhance endothelial NO synthase activity while L-arginine provides the substrate. Practical Recommendations Effective doses range from 2,500–6,000 mg/day, often divided into multiple doses. L-arginine works best for mild-moderate ED and in patients with vascular etiology. The adverse effect rate was 8.3% (vs 2.3% for placebo), primarily gastrointestinal symptoms. Consider combining with Pycnogenol (40–120 mg/day) for enhanced efficacy. Ashwagandha: The Stress-Libido Connection Ashwagandha ( Withania somnifera ) is increasingly recognized for its effects on male sexual function, particularly when stress is a contributing factor. This is where I find it most useful in clinical practice. Chronic stress and elevated cortisol can disrupt hormonal balance, suppress testosterone production, and dampen libido. Ashwagandha's adaptogenic properties help modulate the stress response, which can indirectly support sexual function. Clinical Evidence A 2022 randomized, double-blind, placebo-controlled study published in Health Science Reports  examined ashwagandha root extract (600 mg/day) in 50 adult males with low sexual desire for 8 weeks. Results showed significant improvements in total DISF-M scores (mean difference −9.8; 95% CI: −10.73 to −8.87; p < 0.0001). Serum testosterone levels also increased significantly (mean difference −66.52 ng/dL; p < 0.0001). A 2019 crossover study in aging, overweight males found that 8 weeks of ashwagandha extract was associated with an 18% greater increase in DHEA-S (p = 0.005) and 14.7% greater increase in testosterone (p = 0.010) compared to placebo. An earlier pilot study in psychogenic ED demonstrated that ashwagandha (2,000 mg TID for 60 days) improved erectile function and sexual satisfaction in men with psychologically-mediated dysfunction. How It Works Ashwagandha's withanolides have structural similarity to testosterone and may influence GnRH expression via GABA receptor modulation. Its cortisol-lowering effects may indirectly support testosterone production by reducing HPA axis suppression of the reproductive axis. By supporting healthy stress hormone levels, ashwagandha addresses one of the most overlooked contributors to sexual dysfunction. Practical Recommendations Standard dosing is 300–600 mg/day of standardized root extract (typically KSM-66 or Sensoril formulations) for 8–12 weeks. Ashwagandha is particularly suited for men with stress-related low libido, suboptimal testosterone within normal range, or concurrent anxiety and fatigue. Tribulus Terrestris: Traditional Use Meets Modern Research Tribulus terrestris  has been used traditionally as an aphrodisiac across multiple cultures. The 2023 meta-analysis in Nutrients  identified Tribulus as one of the supplements able to improve male sexual function based on pooled RCT data. Clinical Evidence While much of the robust data comes from female studies, male-specific research shows promising results. The meta-analysis identified Tribulus as demonstrating significant effects on erectile function compared to placebo, though evidence quality remains low to moderate due to heterogeneous study designs. The active constituent protodioscin is believed to influence the hypothalamic-pituitary axis, though direct testosterone elevation has not been consistently demonstrated in human studies. Some researchers suggest the mechanism may involve increased sensitivity to androgens rather than elevated levels. Practical Recommendations Typical dosing ranges from 250–750 mg/day of standardized extract for 4–12 weeks. Side effects are generally mild gastrointestinal symptoms. Given the limited high-quality human data specifically in men, I consider Tribulus an adjunctive therapy rather than primary treatment. Maca: Andean Adaptogen for Desire Maca ( Lepidium meyenii ) is an Andean cruciferous plant traditionally used to enhance fertility and libido. What's interesting about maca is that its effects appear to be hormone-independent—it improves desire without significantly changing testosterone levels. Clinical Evidence A 2023 RCT published in the World Journal of Men's Health  examined maca in patients with late-onset hypogonadism symptoms. After 12 weeks of 3,000 mg/day, significant improvements were observed in AMS (Aging Males' Symptoms), IIEF, and IPSS scores compared to placebo. The ADAM positive rate significantly decreased (p < 0.0001) in the maca group. An earlier systematic review of 4 RCTs found limited but positive evidence for maca improving sexual desire in healthy men and erectile function in men with mild ED (IIEF-5 MD 1.13, 95% CI: 0.64–1.61, p < 0.0001). A pilot study examining SSRI-induced sexual dysfunction found that 3.0 g/day of maca produced significant improvements in ASEX scores, with particular benefits for libido—making it a useful option for patients on antidepressants. Practical Recommendations Effective doses range from 1,500–3,000 mg/day of dried maca root powder for 8–12 weeks. Benefits for sexual desire may appear as early as 8 weeks. Maca is particularly suited for improving desire and may help with SSRI-induced sexual dysfunction. Fenugreek: Testosterone Support and Libido Fenugreek ( Trigonella foenum-graecum ) has emerged as a promising option for supporting testosterone levels and male sexual function, with several well-designed RCTs demonstrating efficacy. Clinical Evidence A 2020 meta-analysis found that fenugreek extract has a significant positive effect on total serum testosterone levels. A 2016 double-blind RCT of Testofen (standardized fenugreek extract) in 120 healthy men aged 43–70 demonstrated significant decreases in AMS scores and improvements in sexual function—including morning erections and frequency of sexual activity—after 12 weeks of 600 mg/day. An earlier RCT in 60 healthy males found that 600 mg/day of Testofen for 6 weeks produced significant improvements in sexual arousal and orgasm, with 81% reporting improvement in libido and 63% improvement in sexual performance quality. A 2018 study in the World Journal of Men's Health  examining a mixed extract of fenugreek and Lespedeza cuneata  in testosterone deficiency syndrome found significant improvements in total and free testosterone, as well as erectile function. How It Works Fenugreek saponins may inhibit aromatase and 5α-reductase, reducing conversion of testosterone to estrogen and DHT respectively. This preserves bioavailable testosterone. Diosgenin, a steroidal saponin in fenugreek, serves as a precursor for steroid hormone synthesis. Practical Recommendations Standard dosing is 500–600 mg/day of standardized fenugreek extract for 6–12 weeks. Fenugreek is particularly suited for aging males with symptoms of androgen decline and men interested in both sexual function and exercise performance benefits. Saffron: Rapid Onset for Erectile Function Saffron ( Crocus sativus ) has shown particularly promising results for erectile dysfunction, with some studies demonstrating improvements in as little as 10 days. This rapid onset makes it unique among the supplements reviewed. Clinical Evidence A 2018 meta-analysis found that saffron had a significantly positive effect on all dimensions of the IIEF questionnaire: erectile function (MD = 5.36), orgasmic function (MD = 1.12), overall satisfaction (MD = 1.23), intercourse satisfaction (MD = 2.18), and sexual desire (MD = 0.78)—all statistically significant. A 2022 double-blind, placebo-controlled RCT in 62 men with ED found that 30 mg/day of saffron for 6 weeks produced improvements in erectile function scores of 6.14 points (95% CI: 4.97–7.30)—exceeding the minimal clinically important difference. The adverse event profile was similar to placebo. Notably, a pilot study found that just 10 days of saffron (200 mg/day) produced significant improvements in IIEF-15 total scores (22.15 to 39.20, p < 0.001) with increased number and duration of erectile events on nocturnal penile tumescence testing. SSRI-Induced Sexual Dysfunction:  A 4-week RCT in men with fluoxetine-related sexual dysfunction found that saffron (30 mg/day) produced significantly greater improvements in erectile function (p < 0.001) and intercourse satisfaction compared to placebo. This makes saffron particularly attractive for patients on antidepressants. How It Works Saffron's active components (crocin, crocetin, and safranal) possess antioxidant, anti-inflammatory, and neuromodulatory properties. The serotonergic effects may explain efficacy in SSRI-induced dysfunction. Antioxidant activity may protect endothelial function and support NO bioavailability. Practical Recommendations Effective doses are 15–30 mg twice daily (30–60 mg/day total) for 4–10 weeks. Saffron appears particularly suited for SSRI-induced sexual dysfunction and mild ED. Cautions include potential interactions with serotonergic medications. Doses above 5 g/day are considered unsafe. Antioxidant Supplementation: The Emerging Evidence A 2025 meta-analysis published in the World Journal of Men's Health  examined 23 double-blind, placebo-controlled trials involving 1,583 men with ED treated with various antioxidant supplements for a median of 12 weeks. The pooled analysis found that antioxidant supplementation significantly improved erectile function with a mean difference of 5.5 points (95% CI: 3.7–7.3; p < 0.001) on the IIEF-EF scale. In subgroup analyses, Pycnogenol and L-arginine combinations showed the most significant benefits. This reinforces what we understand about ED pathophysiology—oxidative stress and endothelial dysfunction play significant roles, and vascular health is foundational to sexual function. Maintaining a diet rich in antioxidants supports these pathways. Important Caveats and Clinical Considerations Evidence Quality:  While these supplements show promising results, evidence quality remains predominantly low to moderate. None should be considered equivalent to PDE-5 inhibitors for established ED. Placebo Response:  Sexual function studies consistently show substantial placebo effects (up to 40%), which complicates interpretation of modest treatment effects. Product Quality:  The 2023 analysis found that 80% of marketed products didn't meet criteria for expected efficacy based on active ingredient doses. I recommend reputable manufacturers using standardized extracts. Underlying Conditions:  ED is often a sentinel marker for cardiovascular disease and metabolic dysfunction. Appropriate medical evaluation should precede or accompany any supplement regimen. A thorough evaluation—including hormone levels and thyroid function—is essential to identify root causes. Lifestyle Foundation:  Exercise, diet, sleep quality, smoking cessation, and weight management remain foundational. Blood pressure, metabolic health, and cardiovascular fitness all directly impact sexual function. Supplements work best as part of a comprehensive approach addressing root causes, not as standalone solutions. Evidence-Based Review: Supplements for Male Sexual Function - Integrative Medicine Functional Medicine Perspective San Antonio TX Practical Summary by Presentation Mild-Moderate Vasculogenic ED:  L-arginine (2,500–6,000 mg/day) ± Pycnogenol; Panax ginseng (900–3,000 mg/day) Stress-Related Low Libido:  Ashwagandha (300–600 mg/day); Maca (1,500–3,000 mg/day) SSRI-Induced Sexual Dysfunction:  Saffron (30 mg BID); Maca (3,000 mg/day) Aging Males Symptoms/Low-Normal Testosterone:  Fenugreek (500–600 mg/day); Ashwagandha (300–600 mg/day) Rapid Onset Needed:  Saffron (may show effects within 10 days) Meet Dr Kim 2026 Meet Yoon Hang Kim MD - expert in integrative & functional medicine and LDN expert At Direct Integrative Care, Dr. Kim is dedicated to guiding you on your path to wellness through a deeply personalized and supportive approach. We focus on integrative medicine, looking beyond symptoms to uncover the root causes of chronic conditions and develop a treatment plan tailored specifically to your unique health journey. By combining compassionate care with innovative therapies, our goal is to empower you with the knowledge and tools needed to achieve lasting health. We invite you to explore our website to learn more about how our patient-centered practice can help you find balance and vitality.  Yoon Hang Kim MD Integrative & Functional Medicine Physician Virtual Practice Serving IA, IL, MO, FL, GA, and TX www.directintegrativecare.com Key References Petre GC et al. Dietary Supplements for Erectile Dysfunction: Analysis of Marketed Products, Systematic Review, Meta-Analysis and Rational Use. Nutrients . 2023;15(17):3677. Ramasamy R et al. Antioxidant Supplementation for Erectile Dysfunction: Systematic Review and Meta-Analysis. World J Mens Health . 2025;43(1). Tian Y et al. Efficacy of L-arginine and Pycnogenol in the treatment of male erectile dysfunction: a systematic review and meta-analysis. Front Endocrinol . 2023;14:1211720. Menafra D et al. Long-term high-dose l-arginine supplementation in patients with vasculogenic erectile dysfunction. J Endocrinol Invest . 2022;45(5):941-961. Rhim HC et al. The Potential Role of Arginine Supplements on Erectile Dysfunction: A Systemic Review and Meta-Analysis. J Sex Med . 2019;16(2):223-234. Lee HW et al. Ginseng for Erectile Dysfunction: A Cochrane Systematic Review. World J Mens Health . 2022;40(2):264-269. Chauhan S et al. Effect of standardized root extract of ashwagandha on well-being and sexual performance in adult males. Health Sci Rep . 2022;5(4):e741. Shin BC et al. Maca (L. meyenii) for improving sexual function: a systematic review. BMC Complement Altern Med . 2010;10:44. Choi YS et al. Efficacy and Safety of Maca in Patients with Late-Onset Hypogonadism. World J Mens Health . 2023;41(3). Rao A et al. Testofen reduces age-related symptoms of androgen decrease and improves sexual function. Aging Male . 2016;19:134-142. Steels E et al. Physiological aspects of male libido enhanced by standardized Trigonella foenum-graecum extract. Phytother Res . 2011;25:1294-1300. Modabbernia A et al. Effect of saffron on fluoxetine-induced sexual impairment in men. Psychopharmacology . 2012;223(4):381-388. Shamsa A et al. Evaluation of Crocus sativus L. (saffron) on male erectile dysfunction. Phytomedicine . 2009;16(8):690-693. Maleki-Saghooni N et al. A systematic review and meta-analysis of clinical trials on saffron effectiveness and safety on erectile dysfunction. Iran J Basic Med Sci . 2018;21(6):554-563. Herbal dietary supplements for erectile dysfunction: A systematic review and meta-analysis. J Herb Med . 2025. Disclaimer: This review is for educational purposes only. Consultation with a healthcare professional is essential prior to initiating any supplement for sexual dysfunction. Individual responses vary, and supplements may interact with medications or underlying conditions. Erectile dysfunction can be a marker of significant cardiovascular disease requiring medical evaluation.